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ABSTRACT 
Background: Major Depressive Disorder (MDD) is moderately heritable, with high prevalence and 
presumed high heterogeneity. Copy number variants (CNVs) could contribute to the heritable component 
of risk, but the two previous genome-wide studies of rare CNVs did not report significant findings. 
Methods: In this meta-analysis of four cohorts (5,780 case and 6,626 control subjects), we analyzed 
association of MDD to (i) genome-wide burden of rare deletions and duplications, partitioned by length 
(<100 kb or >100kb) and other characteristics; and (ii) individual rare exonic CNVs and CNV regions. 
Results: Cases carried significantly more short deletions (P=0.0059), but not long deletions or short or 
long duplications. The confidence interval for long deletions overlapped with that for short deletions, but 
the former were 70% less frequent genome-wide, reducing power to detect increased burden. The 
increased burden of short deletions was primarily in intergenic regions. Short deletions in cases were also 
modestly enriched for high-confidence enhancer regions. No individual CNV achieved thresholds for 
suggestive or significant association after genome-wide correction. P-values <0.01 were observed for 
15q11.2 duplications (TUBGCP5, CYFIP1, NIPA1, NIPA2), deletions in or near PRKN or MSR1, and 
exonic duplications of ATG5. 
Conclusions: The increased burden of short deletions in cases suggests that rare CNVs increase MDD 
risk by disrupting regulatory regions. Results for longer deletions were less clear, but no large effects 
were observed for long multigenic CNVs (as seen in schizophrenia and autism). Further studies with 
larger sample sizes are warranted. 
 
Keywords: major depressive disorder, copy number variation, genome-wide association study, meta-
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Introduction 
 Major depressive disorder (MDD) is a common psychiatric disorder with a lifetime prevalence of 10-
20% (1). It was the third leading cause of global disability in 2015 (2). Heritability is approximately 37%, 
lower than that of several other psychiatric disorders (3). The genome-wide contribution of common 
single nucleotide polymorphisms (SNPs) to MDD risk is approximately 20% (4). Consistent with the 
moderate heritability and high population prevalence, it has required greater than 100,000 MDD cases to 
detect large numbers of genome-wide significant SNP associations, e.g., 15 loci in 121,380 cases plus 
338,101 controls (5), and 44 loci in a partially-overlapping sample (135,458 cases plus 344,901 controls) 
(6).   
 Rare copy number variants (CNVs) could be contributing to the unexplained portion of genetic risk 
and provide information about disease mechanisms. Two previous MDD studies of longer CNVs reported 
no significant genome-wide burden in cases (7, 8). Here, to achieve a larger sample size, we performed a 
meta-analysis of the association of MDD to rare CNVs in 5,780 case and 6,626 control subjects from four 
cohorts. A significant increase of rare, shorter deletions (<100,000 bp) was observed in MDD cases, 
driven by CNVs in intergenic regions.  
Methods and Materials 
 Samples. We studied four European-ancestry cohorts (Table 1). All participants gave signed 
informed consent under protocols approved by the relevant Institutional Review Boards. 
 (A) The RADIANT cohort (7) included cases from three studies of recurrent MDD and two control 
cohorts (458 controls who were screened for lifetime absence of psychiatric disorder; and 2,699 controls 
from phase 2 of the National Blood Service (NBS) WTCCC subcohort). Cases were interviewed with the 
Schedules for Clinical Assessment in Neuropsychiatry (SCAN) (9) and diagnosed with ICD-10 or DSM-
IV criteria. Exclusion criteria were: any history or family history of schizophrenia or bipolar disorder, or 
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 (B) NESDA/NTR. Cases and controls were drawn from the Netherlands Twin Register (NTR) (10) 
and the Netherlands Study of Depression and Anxiety (NESDA) (11). Cases had DSM-IV MDD 
diagnoses by the Composite Interview Diagnostic Instrument (CIDI) (12).  
 (C) GenRED. Cases and controls were from the Genetics of Recurrent Early-Onset Depression 
(GenRED) cohort (13, 14). Cases had a consensus DSM-IV MDD diagnosis based on Diagnostic 
Interview for Genetic Studies (DIGS) interview and other information, with recurrence or chronicity (an 
episode lasting ≥3 years), onset <age 31, ≥1 sibling or parent with recurrent MDD and onset <41, MDD 
independent of substance dependence, no bipolar, schizoaffective disorder or schizophrenia diagnosis, 
and no suspected bipolar-I parent or sibling. The controls (N=1,345) from the Molecular Genetics of 
Schizophrenia (MGS) cohort (15) denied (by online screen) ever meeting DSM-IV MDD gate criteria (no 
two-week period of depressed mood or anhedonia most of the day, nearly every day) – whereas the 
published GenRED GWAS (13) included controls who never met full MDD criteria by online screen (16).  
 (D) GenRED-II. Cases were from the second GenRED GWAS wave (same criteria as GenRED). 
Controls were drawn from the Genomic Psychiatry Cohort (17), Depression Genes and Networks (18),  
and the Mayo Clinic (19). The control cohorts were screened for lifetime depression with a questionnaire, 
SCID interview or medical records, respectively.  
Genotyping. The RADIANT cases and screened controls were genotyped with the HumanHap 
610-Quad Beadchip (Illumina, Inc., San Diego, CA, USA), and the unscreened NBS samples with 
Illumina Infinium 1M beadchips (hg18 for both) (7). The NTR/NESDA (20) and GenRED cohorts were 
genotyped with the Affymetrix Human Genome-Wide SNP 6.0 Array (Affymetrix, Santa Clara, CA, USA) 
(hg18) (14); and GenRED II cases and controls with the Illumina Omni1-Quad beadchip (hg19) (21). 
 Selection of CNV calling algorithms. CNVs had been called with PennCNV (22), QuantiSNP (23) 
and iPattern (24) in the RADIANT dataset (using 562,329 probes common to the two platforms); with 
Birdsuite (25) and PennCNV (22) in NTR/NESDA; with Birdsuite (25) in GenRED; and with QuantiSNP 
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platform. Various authors use a single calling method (8, 26), agreement between two methods (20, 27), 
or more complex approaches (28, 29).  
 Here we conducted a preliminary analysis of CNV call concordance for duplicate genotypes for 115 
Affymetrix 6.0 samples and 20 Illumina Human610-Quad samples. For Affymetrix we compared 
CNVision (28), QuantiSNP (23), PennCNV (22) and Birdsuite (25) and each pair of algorithms, plus the 
addition of CNVision’s pCNV parameter (estimating the probability of a true CNV, based on per-SNP 
variability of Log R Ratio [LRR] and the number of SNPs consistent with a CNV based on B Allele 
Frequency [BAF]). For Illumina we compared all algorithms (except Birdsuite) and pairs, and addition of 
pCNV. We also did the analyses for short (<100 kb) and long (>100 kb) CNVs separately. 
 For Affymetrix, Birdsuite had the highest concordance rate (deletions and duplications), whereas 
combining it with any other method slightly increased concordance but excluded >40% of calls (Table 
S1). Therefore we used Birdsuite alone for Affymetrix data. For Illumina data, QuantiSNP alone had the 
best concordance for deletions (Table S2). For duplications, concordance was highest for QuantiSNP 
alone; calls made by both PennCNV and QuantiSNP showed improved concordance but excluded >30% 
of calls. We used QuantiSNP for primary analyses, plus a secondary “narrow” QuantiSNP+PennCNV 
analysis. For both platforms, concordance was similar for shorter and longer CNVs (Tables S3-S6). 
 Quality control of samples and CNV calls. Exclusion criteria for samples were applied to each 
cohort separately. For NTR/NESDA (20) and GenRED (14), exclusions were applied to samples retained 
by the original studies, using the previous Birdsuite calls: (1) probe intensity variances >4 standard 
deviations (SDs) above cohort mean; (2) total number or length of deletions or duplications >3 SDs above 
the mean; (3) any chromosome with number or length of deletions or duplications >7 SDs above the mean; 
(4) only autosomal CNVs were called. For Illumina data (RADIANT and GenRED II), we re-called 
CNVs with QuantiSNP and PennCNV from raw LRR and BAF data. Exclusion criteria for unfiltered 
calls were: (1) genotype call rate <99%; (2) >5% of SNPs with LRR < -0.5 or > 0.5; (3) >1% of SNPs 
with LRR < -1; (4) BAF drift > 0.01; (5) LRR SD >0.28, (6) waviness factor <0.05 or >-0.05; (7) total 
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 For both platforms, we removed CNVs with <10 probes, and of Birdsuite calls with LOD score <10 
(duplications) or <6 (deletions) and QuantiSNP calls with Maximum Log BF <10. We then merged 
adjacent deletions (copy numbers 0 or 1) or adjacent duplications (Cn 3 or 4) if the number of probes 
separating them was <30% of probes in the merged region (iterating through each chromosome until all 
eligible segments were merged, using an in-house script). We removed CNVs with ≥50% overlap with 
centromeres, telomeres, segmental duplications, or immunoglobulin genes, or length <10 kb (too few 
probes to call reliably) or >4 Mb (in previous work (30), CNVs>4 Mb were disproportionately detected in 
DNA from lymphoblastic cell lines), or with frequency >1% in any of four large-sample cohorts included 
in the Database of Genomic Variants (DGV) (31-34), or with frequency >1% (based on 50% overlap) in 
any of our control cohorts.  
 Statistical analysis overview. All analyses were conducted for post-QC deletions and duplications 
using PLINK and R. Genomic locations with hg18 coordinates were converted to hg19 (UCSC liftOver 
tool). We first determined (as described below) that effects of cohort and sex had to be controlled 
appropriately. We chose primary analyses which directly compute an odds ratio and were equivalent to 
meta-analysis: logistic regression with sex and cohort covariates (for burden tests) or Cochrane-Mantel-
Haenszel (CMH) tests stratified for sex and cohort (for single CNVs), plus meta-analysis and/or 
permutation tests to check results. We tested two main hypotheses, correcting for multiple tests within 
each hypothesis:  
(1) Global burden of rare CNVs is greater in cases vs. controls. The four primary analyses were 
for deletions and duplications, each subdivided by size (<100kb, >100kb); thus the threshold of 
significance was P<0.0125 (0.05/4).  
(2) Cases are more likely to carry specific CNVs. Primary analyses tested association by (i) gene 
(CNVs impacting exon(s) of the gene); and (ii) CNV region defined by pools of overlapping CNVs 
(PLINK). We established thresholds for significant suggestive association as described below (30). Genic 
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and “genic” CNVs were largely overlapping [Table S7] -- 93.2% (deletions) and 99.4% (duplications) of 
long genic CNVs, and 62.6% and 83.6% of short genic CNVs were exonic. 
 Effects of cohort and sex. We evaluated two potential confounding variables: cohort; and sex (the 
female proportion was higher in cases and variable across cohorts). Multiple linear regressions were 
performed for total rare deletions or duplications per subject or summed length (Table S8), with 
case/control status, cohort and sex as independent variables. There were significant effects for cohort 
(deletions and duplications) and sex (deletions).  
 Genome-wide burden analyses were performed for short and long deletions and duplications, using 
logistic regression with sex and cohort as covariates to test for case-control difference. Secondary 
analyses considered intergenic and genic CNVs; separate analyses of exonic and intronic-only CNVs; 
singletons; CNVs >500 kb and >1000 kb; short deletions by 10 kb length bins (10-20, 20-30, etc.). 
Results were checked against: logistic regression for each cohort (with sex as a covariate) followed by 
meta-analysis of the beta coefficients and standard errors (R function “metagen” (35)); and permutation 
tests stratified for cohort and sex (randomly swapping case-control status within the same sex and cohort 
100,000 times using PLINK’s “--within” option).  
 Down-sampled analysis. As a check on the effects of uneven numbers of cases/controls and 
males/females per cohort, we repeated burden analyses using a down-sampled dataset: 1,622 male and 
female cases and controls (6,488 total) drawn from each cohort proportional to its size (Table S9). 
 Analyses of single CNVs. We performed one-sided CMH tests (stratified by sex and cohort) of a 
case excess of exonic CNVs impacting each RefSeq gene, and of CNVs in each “CNV region”; and 
checked results with a stratified permutation tests (results were almost identical). To define regions, we 
used PLINK’s “--segment-group” command to identify 994 CNV “pools” of overlapping post-QC CNVs 
(from all cohorts), and termed the union a CNV region.  
 For any CNV with nominally increased case frequency (CMH P<0.01), we carried out additional 
filtering because calling artifacts often produce “significant” results for rare events. We visualized 
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LRR a plot of estimated probe-by-probe copy number using a different algorithm (36). We also plotted all 
CNVs in the region. We excluded CNVs for which the probewise algorithm showed no copy number 
change. After excluding genes/regions where most calls were considered artifacts, or were the edges of a 
common CNV region, we re-computed the CMH tests. We computed a proportion test across the four 
cohorts for each gene/region and excluded those with significant heterogeneity (P<3.53E-05 to correct for 
multiple tests, see below). Table S10 lists the inspected regions and reasons for all exclusions. 
 Additional exploratory analyses (permutation tests) considered each transcript 
(http://genome.ucsc.edu/), ENCODE regulatory region, Roadmap Project putative enhancer, promoter and 
dyadic region, and in aggregate for lists of CNVs with reported associations to psychiatric disorders (29, 
37) or developmental delay (32). 
 We used a previously-described method (30) to estimate thresholds for significant association 
(expected by chance once in 20 genome-wide studies) and suggestive association (expected once per 
study). For all 994 CNV regions, the 329 deletion regions intersected with 487 genes, and 665 duplication 
regions intersected with 1,475 genes (totaling 1,962 genic tests). However, tests of genes within a region 
are correlated, and each region contained 4.64 genes on average. Thus the 1,962 genic tests represented 
~1962/4.64=423 independent tests. We corrected for 1,417 tests (994 regions and 423 genes), a 
conservative estimate because some regions were partially overlapping, and many genes were in more 
than one region, resulting in a P-value threshold for significant association of 0.05/1417=3.53E-05, and 
for suggestive association, 1.0/1417=7.06E-04. 
Power analysis. Power analyses were conducted for detection of specific CNVs (Figure S1). For 
the ranges of allele frequencies and genotypic relative risks that were observed in this study, power was 
good-excellent to detect associations at P=0.01, but detection of suggestive or significant association 
would have required larger relative risks than were observed here. 
 Enrichment analysis of functional pathways. To detect gene sets associated with MDD, pathways 
from Kyoto Encyclopedia of Genes and Genomes (KEGG, http://rest.kegg.jp/list/pathway) and Gene 
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enrichment methods (38) were used to test for enrichment of CNVs (separately for all or exonic CNVs) in 
all the genes of each pathway relative to all genic CNVs using ‘--cnv-enrichment-test’ in PLINK. 
Permutation tests of enrichment in cases were also performed by adding '--mperm 10000' in PLINK, with 
batch and sex as covariates. A set of schizophrenia-associated genes (39) was also tested.  
We also evaluated whether case CNVs were enriched in high-confidence DNaseI regions (-
log10(p)>= 10) from ENCODE (40) or Roadmap Epigenomics Project (41) (downloaded from 
https://personal.broadinstitute.org/meuleman/reg2map/HoneyBadger2_release/). Separately for promoter, 
enhancer and dyadic regions, we analyzed all tissues together (i.e., whether more case short deletions 
intersected with at least one high-confidence regulatory sequence from any tissue), and then each tissue 
separately (counting high-confidence sequences for that tissue). For intergenic short deletions, averaged 
across tissues, the proportion of CNVs that overlap high-confidence regulatory regions was 1.3% for 
promoter regions, 2.0% (dyadic regions) and 14.9% (enhancer regions). 
RESULTS 
 Of 14,429 samples, 12,406 passed QC (5,780 cases and 6,626 controls, Table 1). Total numbers of 
rare deletion and duplication calls are shown in Table S11.  
Genome-wide burden. Cases had more CNVs per subject for rare, short (<100 kb) deletions 
(P=0.00592, odds ratio = 1.0483), driven by intergenic deletions (P=0.00714, OR=1.0716) (Table 2; and 
by cohort, Table S12). Similar results were observed by the primary logistic regression tests (Table S13), 
meta-analysis of cohort-specific logistic regressions (Table S14), stratified permutation tests (Table S7) 
and the downsampled dataset (Table S9). Short deletions across the 10-100kb range contributed to the 
case-control difference (Table S15; Figures S2-S3). No significant differences were observed for 
duplications or long deletions, but the OR for long deletions was positive (1.03), the confidence interval 
overlapped with that for short deletions (Table 2), and a secondary analysis of all rare deletions was 
significant (OR=1.044; CI=1.013-1.075; P=0.0046; Table S16). No significant effect was observed for 
singleton or very long (>500 kb, > 1000 kb) deletions or duplications. There was no evidence of strong 
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(P=0.14) (Table S14; and Table S12 and Figure S4 for results by cohort). The excess of short deletions in 
cases became more significant when CNVs with frequency >1% in each cohort separately were excluded 
(rather than >1% in any cohort) (Table S17); or when QuantiSNP+PennCNV calls were required for 
Illumina data (Table S18). Burden results did not change after excluding nominally significant CNV 
regions that failed manual checks (Table S19). 
We considered two possible within-cohort confounding factors: DNA source and genotyping 
platforms. In GenRED II, there were two DNA sources: blood (137 cases and all controls) or 
lymphoblastic cell lines (674 cases) (Table S20). CNV burden did not significantly differ between blood 
vs. LCL case DNAs for any category, with a trend for more long deletions in LCL DNA (Table S21). 
RADIANT CNV calls used probes common to Illumina 610-Quad (assayed in cases and screened 
controls) and Illumina 1M (unscreened controls). Burden results were similar for cases vs. screened or 
unscreened controls, except that cases had more short deletions than screened controls (assayed with the 
same array) (Table S22). Thus, neither factor accounted for the main finding. 
 Exonic CNVs and CNV regions. After all QC, no gene or region met criteria for significant or 
suggestive association (Table S10). Results with P<0.01 are shown in Table 3. These represent four 
independent loci. Duplications in 15q11.2 achieved P=0.00076 (OR=3.88). These duplications are 
reciprocal to a well-known deletion region (see Discussion), consistently impacting four genes. Less 
consistent results are observed in surrounding genes in segmental duplication regions (Table S10). Exonic 
deletions in MSR1 achieve P=0.0019 (OR=1.96); the region test includes several intronic deletions, with a 
similar result (P=0.00075, OR=2.05). A CNV region containing exonic and intronic deletions in PRKN 
(formerly PARK2) produced P=0.00097 (OR=1.92); the exonic test for PRKN had P>0.01. Finally, there 
were 6 duplications, all in cases, in 6q21 (P=0.0059, OR=∞), including 5 exonic duplications in ATG5 
that overlapped with one upstream duplication. LRR/BAF plots of CNVs shown in Table 3 are provided 
in Figure S5. 
 Pathway enrichment analysis. After correction for multiple testing, no KEGG or GO pathway was 
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  Regulatory regions. Enhancer regions were modestly enriched in cases for all tissues combined as 
defined above (P=0.024), and in 5 of 127 specific tissues (P<0.05) (Table S23).   
 Known loci associated with psychiatric disorders or developmental delay. Permutation tests did 
not demonstrate case enrichment of CNVs in loci associated with psychiatric disorders (Table S24) or 
developmental delay (Table S25). There was no overlap between the CNVs reported in Table 3 and 
significant MDD GWAS loci (6, 42). 
Discussion 
 This is the largest genome-wide study to date of the association of MDD with rare CNVs. An excess 
of long CNVs (>100 kb) was initially reported in an analysis of the RADIANT cohort that included 
additional controls with DNA from buccal swabs (43), but a subsequent re-analysis (without the extra 
controls and with stricter QC, producing a substantial reduction in number of CNVs per subject similar to 
that reported here) detected no significant excess (7). Another study of longer CNVs in 452 treatment-
resistant depression cases and 811 controls also reported no significant differences (8). For schizophrenia, 
evidence for association of several long CNVs with large effects on risk could be detected with samples 
comparable in size to RADIANT (44). There were no such findings for single CNVs in the present, larger 
study. Thus it appears that very long, multigenic CNVs are less likely to have large effects on the risk of 
MDD.  
 Global burden of short deletions. We observed enrichment of short deletions (<100 kb) in cases, 
and particularly intergenic deletions. This suggests that the effect on MDD risk is due to deletion of 
regulatory elements, consistent with the (modest) enrichment of high-confidence enhancer regions in 
short deletions in cases. This is consistent with the extensive analyses of the Psychiatric Genomics 
Consortium’s meta-analysis of depression GWAS data (6) which detected 44 significant associations 
primarily in non-exonic SNPs, including several in genes that are involved with extensive regulatory 
networks (RBFOX1, RBFOX2, RBFOX3, CELF4), as well as genome-wide enrichment of highly 
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 One might expect an increased burden of longer CNVs as well, because they contain more genes and 
regulatory elements. We analyzed short and long deletions separately because longer CNVs have been 
more frequently implicated in disease risk. Similar ORs were observed for burden of short and of long 
deletions in cases, and their confidence intervals overlapped, but we had less power to detect an excess of 
long deletions because they were 70% less frequent than short deletions. Thus, an increased burden of 
longer deletions might be observed in larger meta-analyses. We also suspect that the ascertainment 
methods of most MDD studies are biased against individuals with long multigenic CNVs, whose carriers 
are at higher risk of disorders such as schizophrenia, autism and intellectual disability. Individuals with 
these phenotypes are at increased risk of depression (45, 46), but they are often excluded from MDD 
cohorts, and are often not specifically diagnosed with, or treated for, depression (resulting in exclusion 
even from registry-based cohorts). Thus, both short and long rare deletions could impact on risk of MDD, 
but the current results are significant only for shorter deletions (10-100kb), and larger cohorts will be 
needed to resolve the issue. 
 Individual genes and regions. No significant or suggestive associations were detected for individual 
exonic CNVs or for CNV regions, after conservative correction for genome-wide testing. Larger datasets 
will be needed to identify true positive findings. Nominal association was observed in several regions 
(P<0.01 but not achieving suggestive or significant thresholds): (i) 15q11.2 duplications encompassing 
the small, non-imprinted BP1-BP2 segment of the Prader-Willi/Angelman region. Deletions of this 
segment are weakly associated with risk of schizophrenia (29, 37), and have been reported to be 
associated with dyslexia and dyscalculia (with deletions and duplications associated with reductions or 
increases, respectively, in size and activity of the left fusiform gyrus) (47). (ii) Deletions in exons of 
MSR1 (Macrophage Scavenger Receptor 1) (or all deletions in that region), implicated in atherosclerosis, 
Alzheimer’s disease and host defense. (iii) Deletions in 6q26 impacting introns or exons of PRKN (Parkin 
RBR E3 Ubiquitin Protein Ligase), where recessive mutations cause early-onset Parkinson’s disease (PD) 
(type 2) but heterozygous variants are not associated with PD (48), although PD is associated with 
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(Autophagy Related 5). ATG5 has multiple immune functions including negative regulation of the type I 
interferon production pathway, which is of note because reduced white blood cell expression of interferon 
I response genes was reported (18), but not replicated (50) in studies of MDD. 
 Limitations. The sample size is larger than previous CNV studies of MDD, but remains 
underpowered. Combining CNV cohorts presents challenges including differences in clinical methods 
(inclusion criteria, ascertainment, assessments) and genotyping (platforms which differ in genome 
coverage and signal:noise ratio). Also, the present cohorts are not ideal for testing whether the long, 
multigenic “neuropsychiatric” CNVs are also predisposing for depression: the psychiatric and 
neurological features of these CNVs may be considered exclusion criteria from MDD studies; and the 
associated cognitive impairments reduce the probability of being recruited into MDD cohorts because 
individual carriers are less likely to volunteer or to be treated in the targeted clinical settings. On the other 
hand, the cohorts are broadly representative of the current concept of clinically significant MDD. 
 Conclusion. In MDD cases from four cohorts, we found significant evidence for an increased global 
burden of shorter rare deletions, which was mainly driven by intergenic deletions. The evidence regarding 
longer deletions was inconclusive: they were not significantly increased in cases, but the confidence 
intervals overlapped with the case-control ORs for shorter and longer deletions, and there was less power 
to detect a difference because longer deletions are less frequent. Overall, the results suggest that the 
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Table 1. Cohorts and sample sizes before and after QC filtering 










RADIANT 3,087 (908/2,179) 3,157 (1,522/1,635) 2,460 (724/1,736) 2,587 (1,240/1,347) 
NESDA/NTR 1,637 (509/1,128) 2,030 (765/1,265) 1,568 (488/1,080) 1,913 (719/1,194) 
GenRED I 1,089 (319/770) 1,345 (784/561) 941 (271/670) 1,264 (743/521) 
GenRED II 831 (144/687) 944 (418/526) 811 (139/672) 862 (384/478) 















Table 2. Genome-wide burden analyses of  
long and short deletions and duplications (CNVs/subject) 
 
CNV type  CNVs/subject OR 95% CI p value Cases Cont 
Deletions 
>100kb — All 0.324 0.318 1.0296 0.9658-1.0975 3.71E-01 
    Intergenic 0.134 0.138 0.9881 0.8956-1.0899 8.11E-01 
    Genic 0.191 0.181 1.0606 0.9754-1.1531 1.68E-01 
      Exonic 0.175 0.168 1.0521 0.9646-1.1475 2.51E-01 
      Intronic 0.015 0.012 1.1672 0.8591-1.5876 3.23E-01 
<100kb — All 1.015 0.978 1.0483 1.0139-1.0843 5.92E-03 
    Intergenic 0.506 0.483 1.0716 1.0190-1.1270 7.14E-03 
    Genic 0.509 0.495 1.0343 0.9877-1.0842 1.56E-01 
      Exonic 0.330 0.310 1.0552 0.9965-1.1192 6.95E-02 
      Intronic 0.179 0.185 0.9952 0.9149-1.0825 9.11E-01 
Duplications 
>100kb — All 0.496 0.476 1.0268 0.9837-1.0725 2.29E-01 
    Intergenic 0.087 0.079 1.0912 0.9654-1.2333 1.62E-01 
    Genic 0.409 0.397 1.0187 0.9723-1.0677 4.37E-01 
      Exonic 0.406 0.395 1.0166 0.9702-1.0657 4.89E-01 
      Intronic 0.004 0.002 1.5254 0.7880-3.0095 2.13E-01 
<100kb — All 0.670 0.702 0.9850 0.9512-1.0194 3.90E-01 
    Intergenic 0.252 0.266 0.9788 0.9166-1.0449 5.21E-01 
    Genic 0.418 0.436 0.9845 0.9410-1.0296 4.96E-01 
      Exonic 0.345 0.365 0.9730 0.9253-1.0225 2.83E-01 
      Intronic 0.073 0.072 1.0586 0.9285-1.2066 3.94E-01 
 
For rare CNVs (carried by <1% of controls in each cohort), we defined four primary case-control tests of CNV subsets: 
deletions and duplications, and within each type, long (>100kb) and short (<100kb). For each subset, case-control 
difference in CNVs per subject was tested by logistic regression, stratified for cohort and sex (Bonferroni-corrected 
threshold of significance p=0.05/4=0.0125 (significant result shown in bold italics). Further exploration then considered 
genomic location: only intergenic, genic (exonic and/or intronic impact), exonic (subset of genic), and only intronic 















Table 3. CNV genes and regions (p<0.01 case-control difference) 
 
Gene or 
region    
ALL CMH test RAD GR2 GR1 Neth 




               MSR1 8 15,965,386 16,050,300 55 32 1.96 1.9E-03 23 10 6 3 15 10 11 9 
 Dup         
        
TUBGCP5 15 22,833,394 22,873,891 
24 7 3.88 7.6E-04 7 3 11 0 2 1 4 3 15q11.2 (reciprocal to well-known deletion region) 
CYFIP1 15 22,892,648 23,003,603 
NIPA2 15 23,004,683 23,034,427 
NIPA1 15 23,043,278 23,086,843 
Regions (genic and/or intergenic) 
Del 
 
               6q26 6 162,136,159 163,489,668 65 40 1.92 9.7E-04 33 17 10 11 9 5 13 7 PRKN 
8p22 8 15,817,196 16,092,656 59 33 2.05 7.5E-04 24 10 18 11 6 3 11 9 MSR1 
Dup                 
6q21 6 106,549,398 107,026,323 6 0  Inf  5.9E-03 2 0 1 0 0 0 3 0 ATG5 
15q11.2 15 22,652,330 23,309,294 24 7   3.88 7.6E-04 7 3 2 1 11 0 4 3 TUBGCP5, CYFIP1, NIPA1, NIPA2 
 
Shown are the numbers of cases (out of 5,780) and of controls (out of 6,626) carrying each CNV with post-QC P<0.01. Del=deletions; 
Dup=duplications; Chr=chromosome; Start and End are genomic positions in base pairs (build HG19) either for the gene for which one or more 
exons was impacted by each CNV, or for the region within which CNVs were counted. Cont=control; CMH=Cochrane-Mantel-Haenszel; OR = 
CMH odds ratio; Ca=case; Co=controls; GR2=GenRED2 (Illumina); GR1=GenRED1 (Affymetrix); Neth=NESDA/NTR (Affymetrix); RAD = 
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Comparative analyses of multiple CNV calling algorithms 
Concordance analyses were restricted to calls after quality control. But when considering whether a call 
in specimen 1 was concordant with specimen 2, we used CNV calls of Specimen 2 before quality control 
as even a sub-threshold call could provide some evidence for the existence of a CNV. A CNV call was 
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# S1 12.56 11.36 10.78 10.41 11.12 10.40 10.18 20.10 11.12 10.41 
# S2 12.44 11.44 10.89 10.56 11.00 10.35 10.17 20.46 11.17 10.42 
% S1 by S2 0.77 0.79 0.82 0.82 0.84 0.86 0.86 0.92 0.95 0.95 
% S2 by S1 0.80 0.82 0.84 0.85 0.86 0.88 0.88 0.91 0.95 0.97 
pCNV<0.05 
# S1 10.47 9.73 9.45 9.06 9.83 9.43 9.16 9.28 8.90 8.68 
# S2 10.18 9.55 9.30 8.98 9.65 9.32 9.07 8.93 8.69 8.50 
% S1 by S2 0.83 0.84 0.85 0.86 0.86 0.87 0.88 0.95 0.96 0.96 
% S2 by S1 0.85 0.87 0.88 0.88 0.89 0.90 0.90 0.97 0.97 0.98 
pCNVlrr<0.05 
# S1 11.68 10.72 10.26 9.88 10.48 9.98 9.68 10.54 9.85 9.50 
# S2 11.57 10.85 10.47 10.11 10.47 10.03 9.77 10.75 9.90 9.57 
% S1 by S2 0.79 0.80 0.82 0.83 0.84 0.86 0.86 0.94 0.96 0.96 
% S2 by S1 0.82 0.84 0.85 0.86 0.87 0.88 0.88 0.96 0.97 0.97 
pCNVbaf<0.05 
# S1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 0.01 
# S2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
% S1 by S2 NA NA NA NA NA NA NA 0.50 1.00 1.00 
% S2 by S1 NA NA NA NA NA NA NA NA NA NA 
pCNV<0.05 or 
pCNVlrr<0.05 
# S1 11.68 10.72 10.26 9.88 10.48 9.98 9.68 10.54 9.85 9.50 
# S2 11.57 10.85 10.47 10.11 10.47 10.03 9.77 10.75 9.90 9.57 
% S1 by S2 0.79 0.80 0.82 0.83 0.84 0.86 0.86 0.94 0.96 0.96 
% S2 by S1 0.82 0.84 0.85 0.86 0.87 0.88 0.88 0.96 0.97 0.97 
pCNV<0.05 or 
pCNVbaf<0.05 
# S1 10.47 9.73 9.45 9.06 9.83 9.43 9.16 9.29 8.91 8.69 
# S2 10.18 9.55 9.30 8.98 9.65 9.32 9.07 8.93 8.69 8.50 
% S1 by S2 0.83 0.84 0.85 0.86 0.86 0.87 0.88 0.95 0.96 0.96 
% S2 by S1 0.85 0.87 0.88 0.88 0.89 0.90 0.90 0.97 0.97 0.98 
pCNVlrr<0.05 or 
pCNVbaf<0.05 
# S1 11.68 10.72 10.26 9.88 10.48 9.98 9.68 10.55 9.86 9.50 
# S2 11.57 10.85 10.47 10.11 10.47 10.03 9.77 10.75 9.90 9.57 
% S1 by S2 0.79 0.80 0.82 0.83 0.84 0.86 0.86 0.94 0.96 0.96 




# S1 11.68 10.72 10.26 9.88 10.48 9.98 9.68 10.55 9.86 9.50 
# S2 11.57 10.85 10.47 10.11 10.47 10.03 9.77 10.75 9.90 9.57 
% S1 by S2 0.79 0.80 0.82 0.83 0.84 0.86 0.86 0.94 0.96 0.96 
% S2 by S1 0.82 0.84 0.85 0.86 0.87 0.88 0.88 0.96 0.97 0.97 
 



































# S1 9.34 8.27 7.42 4.15 8.39 7.27 4.04 5.68 3.00 2.97 
# S2 9.72 8.57 7.88 4.36 8.76 7.51 4.45 5.80 3.13 3.02 
% S1 by S2 0.70 0.72 0.74 0.80 0.76 0.79 0.83 0.81 0.92 0.92 
% S2 by S1 0.68 0.70 0.73 0.74 0.73 0.76 0.79 0.79 0.94 0.94 
pCNV<0.05 
# S1 1.76 1.64 1.59 1.47 1.71 1.66 1.50 1.43 1.37 1.36 
# S2 1.58 1.63 1.58 1.42 1.63 1.58 1.43 1.27 1.25 1.25 
% S1 by S2 0.85 0.88 0.88 0.90 0.87 0.89 0.89 0.95 0.97 0.97 
% S2 by S1 0.90 0.89 0.90 0.91 0.95 0.95 0.97 0.97 0.97 0.97 
pCNVlrr<0.05 
# S1 6.61 6.18 5.76 3.01 6.38 5.80 2.97 2.46 2.28 2.28 
# S2 6.47 6.07 5.87 2.97 6.50 5.88 3.18 2.36 2.26 2.18 
% S1 by S2 0.73 0.75 0.76 0.82 0.78 0.80 0.82 0.93 0.95 0.95 
% S2 by S1 0.72 0.75 0.76 0.78 0.77 0.80 0.82 0.94 0.95 0.95 
pCNVbaf<0.05 
# S1 0.99 0.97 0.94 0.90 0.97 0.94 0.90 0.90 0.85 0.85 
# S2 0.90 0.94 0.90 0.88 0.89 0.87 0.85 0.85 0.83 0.83 
% S1 by S2 0.91 0.91 0.91 0.93 0.91 0.92 0.91 0.96 0.97 0.97 
% S2 by S1 0.94 0.90 0.91 0.90 0.97 0.97 0.97 0.99 0.99 0.99 
pCNV<0.05 or 
pCNVlrr<0.05 
# S1 6.85 6.38 5.92 3.18 6.58 5.97 3.16 2.67 2.47 2.45 
# S2 6.67 6.30 6.10 3.19 6.71 6.09 3.39 2.56 2.46 2.37 
% S1 by S2 0.74 0.76 0.77 0.83 0.79 0.81 0.83 0.94 0.95 0.95 
% S2 by S1 0.74 0.75 0.76 0.79 0.78 0.81 0.83 0.95 0.95 0.96 
pCNV<0.05 or 
pCNVbaf<0.05 
# S1 1.81 1.69 1.63 1.50 1.75 1.70 1.53 1.44 1.38 1.37 
# S2 1.62 1.66 1.60 1.43 1.64 1.58 1.44 1.29 1.26 1.27 
% S1 by S2 0.84 0.88 0.89 0.90 0.87 0.89 0.89 0.95 0.97 0.97 
% S2 by S1 0.90 0.90 0.90 0.91 0.95 0.95 0.97 0.97 0.97 0.97 
pCNVlrr<0.05 or 
pCNVbaf<0.05 
# S1 6.87 6.41 5.96 3.21 6.60 5.99 3.17 2.67 2.46 2.45 
# S2 6.71 6.32 6.10 3.19 6.71 6.08 3.39 2.57 2.46 2.38 
% S1 by S2 0.74 0.76 0.77 0.83 0.79 0.81 0.84 0.94 0.95 0.95 




# S1 6.89 6.43 5.96 3.22 6.62 6.01 3.18 2.69 2.48 2.47 
# S2 6.71 6.34 6.11 3.21 6.72 6.09 3.40 2.57 2.47 2.39 
% S1 by S2 0.74 0.76 0.77 0.83 0.79 0.81 0.84 0.94 0.95 0.95 
% S2 by S1 0.74 0.75 0.77 0.79 0.78 0.81 0.83 0.95 0.95 0.96 
 






















Affymetrix All CNVs 
CNVision PennCNV PennCNV + QuantiSNP 
PennCNV 










# S1 21.90 19.63 18.20 14.56 19.51 17.67 14.23 25.78 14.12 13.38 
# S2 22.16 20.01 18.77 14.91 19.76 17.86 14.62 26.26 14.30 13.43 
% S1 by S2 0.74 0.76 0.78 0.81 0.81 0.83 0.85 0.90 0.95 0.95 
% S2 by S1 0.74 0.76 0.78 0.81 0.80 0.82 0.85 0.89 0.95 0.96 
pCNV<0.05 
# S1 12.24 11.37 11.04 10.53 11.55 11.10 10.66 10.70 10.28 10.03 
# S2 11.76 11.17 10.88 10.40 11.29 10.90 10.50 10.20 9.94 9.75 
% S1 by S2 0.83 0.85 0.86 0.86 0.86 0.88 0.88 0.95 0.96 0.96 
% S2 by S1 0.85 0.87 0.88 0.89 0.89 0.91 0.91 0.97 0.97 0.97 
pCNVlrr<0.05 
# S1 18.29 16.90 16.02 12.89 16.86 15.78 12.65 13.00 12.13 11.77 
# S2 18.04 16.92 16.34 13.09 16.97 15.91 12.95 13.10 12.16 11.75 
% S1 by S2 0.77 0.78 0.80 0.83 0.82 0.83 0.85 0.94 0.96 0.96 
% S2 by S1 0.78 0.80 0.81 0.84 0.82 0.84 0.86 0.95 0.96 0.96 
pCNVbaf<0.05 
# S1 0.99 0.97 0.94 0.90 0.97 0.94 0.90 0.91 0.86 0.86 
# S2 0.90 0.94 0.90 0.88 0.89 0.87 0.85 0.85 0.83 0.83 
% S1 by S2 0.91 0.91 0.91 0.93 0.91 0.92 0.91 0.95 0.97 0.97 
% S2 by S1 0.94 0.90 0.91 0.90 0.97 0.97 0.97 0.99 0.99 0.99 
pCNV<0.05 or 
pCNVlrr<0.05 
# S1 18.53 17.10 16.18 13.06 17.06 15.96 12.83 13.21 12.32 11.95 
# S2 18.24 17.16 16.57 13.30 17.18 16.12 13.16 13.30 12.36 11.94 
% S1 by S2 0.77 0.78 0.80 0.83 0.82 0.84 0.85 0.94 0.96 0.96 
% S2 by S1 0.78 0.80 0.81 0.84 0.82 0.84 0.86 0.95 0.96 0.96 
pCNV<0.05 or 
pCNVbaf<0.05 
# S1 12.28 11.42 11.08 10.57 11.58 11.13 10.69 10.73 10.30 10.06 
# S2 11.80 11.21 10.90 10.42 11.30 10.90 10.51 10.22 9.95 9.77 
% S1 by S2 0.83 0.85 0.86 0.87 0.86 0.88 0.88 0.95 0.96 0.96 
% S2 by S1 0.86 0.87 0.88 0.89 0.89 0.91 0.91 0.97 0.97 0.97 
pCNVlrr<0.05 or 
pCNVbaf<0.05 
# S1 18.55 17.13 16.22 13.09 17.08 15.97 12.84 13.22 12.32 11.96 
# S2 18.28 17.17 16.57 13.30 17.18 16.11 13.16 13.31 12.36 11.95 
% S1 by S2 0.77 0.78 0.80 0.83 0.82 0.84 0.85 0.94 0.96 0.96 




# S1 18.57 17.15 16.22 13.10 17.10 15.99 12.86 13.23 12.34 11.97 
# S2 18.29 17.19 16.58 13.32 17.19 16.12 13.17 13.32 12.37 11.96 
% S1 by S2 0.77 0.78 0.80 0.83 0.82 0.84 0.85 0.94 0.96 0.96 
% S2 by S1 0.78 0.80 0.81 0.84 0.82 0.84 0.86 0.95 0.96 0.96 
 
# S1,2 = N(CNVs) detected in sample 1 or 2 of each pair of duplicates. 
% S1 by S2 = proportion of S1 CNVs detected (50% overlap) in S2 - with no filtering of S2. 
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# S1 8.95 7.70 8.10 6.15 6.70 6.40 5.00 4.60 3.80 4.60 2.55 2.70 3.50 2.35 2.10 
# S2 8.70 7.60 7.80 6.00 6.75 6.35 5.25 4.55 3.95 4.75 2.35 2.35 3.25 2.05 2.00 
% S1 by S2 0.86 0.87 0.89 0.97 0.93 0.94 0.96 1.00 1.00 0.98 0.59 0.65 0.74 0.88 0.73 
% S2 by S1 0.86 0.87 0.91 0.96 0.92 0.93 0.86 0.94 0.95 0.89 0.69 0.81 0.89 0.99 0.92 
pCNV < 0.05 
# S1 6.15 5.50 5.60 4.95 5.35 4.50 3.85 3.65 3.15 3.75 1.65 1.65 1.95 1.80 1.60 
# S2 6.05 5.40 5.50 4.95 5.35 4.35 3.60 3.45 3.10 3.55 1.70 1.80 2.05 1.85 1.80 
% S1 by S2 0.94 0.94 0.98 0.98 0.95 0.98 0.96 1.00 1.00 0.97 0.82 0.87 0.92 0.93 0.87 
% S2 by S1 0.96 0.94 0.98 0.99 0.94 1.00 0.92 0.98 0.99 0.91 0.85 0.99 0.99 0.99 0.99 
pCNVlrr < 0.05 
# S1 7.15 6.20 6.35 5.10 5.65 5.05 4.20 4.05 3.40 4.10 2.10 2.00 2.30 1.70 1.55 
# S2 6.80 5.85 6.30 4.90 5.55 4.90 4.15 3.95 3.40 4.05 1.90 1.70 2.35 1.50 1.50 
% S1 by S2 0.88 0.88 0.92 0.96 0.92 0.98 0.97 1.00 1.00 0.97 0.62 0.66 0.79 0.84 0.75 
% S2 by S1 0.90 0.88 0.95 0.99 0.91 0.96 0.87 0.98 0.99 0.88 0.73 0.87 0.91 0.99 0.99 
pCNVbaf < 0.05 
# S1 1.30 1.35 1.65 1.50 1.35 0.00 0.00 0.00 0.00 0.00 1.30 1.35 1.65 1.50 1.35 
# S2 1.50 1.60 1.80 1.60 1.60 0.00 0.00 0.00 0.00 0.00 1.50 1.60 1.80 1.60 1.60 
% S1 by S2 0.93 0.96 0.98 1.00 0.96 NA NA NA NA NA 0.93 0.96 0.98 1.00 0.96 
% S2 by S1 0.87 1.00 1.00 1.00 1.00 NA NA NA NA NA 0.87 1.00 1.00 1.00 1.00 
pCNV < 0.05 or 
pCNVlrr < 0.05 
# S1 7.35 6.50 6.80 5.45 5.95 5.05 4.20 4.05 3.40 4.10 2.30 2.30 2.75 2.05 1.85 
# S2 7.10 6.20 6.80 5.35 5.90 4.90 4.15 3.95 3.40 4.05 2.20 2.05 2.85 1.95 1.85 
% S1 by S2 0.89 0.88 0.92 0.96 0.93 0.98 0.97 1.00 1.00 0.97 0.62 0.67 0.80 0.88 0.77 
% S2 by S1 0.89 0.89 0.95 0.99 0.92 0.96 0.87 0.98 0.99 0.88 0.71 0.89 0.92 0.99 0.99 
pCNV < 0.05 or 
pCNVbaf < 0.05 
# S1 6.15 5.50 5.60 4.95 5.35 4.50 3.85 3.65 3.15 3.75 1.65 1.65 1.95 1.80 1.60 
# S2 6.05 5.40 5.55 4.95 5.35 4.35 3.60 3.45 3.10 3.55 1.70 1.80 2.10 1.85 1.80 
% S1 by S2 0.94 0.94 0.98 0.98 0.95 0.98 0.96 1.00 1.00 0.97 0.82 0.87 0.92 0.93 0.87 
% S2 by S1 0.96 0.94 0.98 0.99 0.94 1.00 0.92 0.98 0.99 0.91 0.85 0.99 0.99 0.99 0.99 
pCNVlrr < 0.05 
or pCNVbaf < 
0.05 
# S1 7.35 6.50 6.80 5.45 5.95 5.05 4.20 4.05 3.40 4.10 2.30 2.30 2.75 2.05 1.85 
# S2 7.10 6.20 6.85 5.35 5.90 4.90 4.15 3.95 3.40 4.05 2.20 2.05 2.90 1.95 1.85 
% S1 by S2 0.89 0.88 0.92 0.96 0.93 0.98 0.97 1.00 1.00 0.97 0.62 0.67 0.80 0.88 0.77 
% S2 by S1 0.89 0.89 0.95 0.99 0.92 0.96 0.87 0.98 0.99 0.88 0.71 0.89 0.92 0.99 0.99 
pCNV < 0.05 or 
pCNVlrr < 0.05 
or pCNVbaf < 
0.05 
# S1 7.35 6.50 6.80 5.45 5.95 5.05 4.20 4.05 3.40 4.10 2.30 2.30 2.75 2.05 1.85 
# S2 7.10 6.20 6.85 5.35 5.90 4.90 4.15 3.95 3.40 4.05 2.20 2.05 2.90 1.95 1.85 
% S1 by S2 0.89 0.88 0.92 0.96 0.93 0.98 0.97 1.00 1.00 0.97 0.62 0.67 0.80 0.88 0.77 
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Affymetrix Short Deletions (<100 kb) 












# S1 10.35 9.29 8.83 8.57 9.27 8.59 8.51 16.52 9.32 8.56 
# S2 10.25 9.37 8.93 8.73 9.09 8.45 8.49 16.81 9.36 8.57 
% S1 by S2 0.77 0.78 0.80 0.81 0.83 0.85 0.86 0.92 0.95 0.95 
% S2 by S1 0.80 0.82 0.84 0.84 0.85 0.88 0.87 0.92 0.96 0.97 
pCNV<0.05 
# S1 8.84 8.13 7.90 7.58 8.31 7.92 7.77 7.91 7.58 7.32 
# S2 8.57 8.01 7.80 7.57 8.12 7.79 7.67 7.50 7.29 7.06 
% S1 by S2 0.81 0.82 0.83 0.84 0.85 0.86 0.87 0.95 0.96 0.96 
% S2 by S1 0.84 0.86 0.87 0.87 0.87 0.89 0.89 0.97 0.97 0.97 
pCNVlrr<0.05 
# S1 9.75 8.90 8.52 8.21 8.82 8.33 8.16 8.93 8.33 7.93 
# S2 9.64 8.97 8.66 8.41 8.70 8.27 8.17 9.01 8.29 7.90 
% S1 by S2 0.78 0.78 0.80 0.81 0.83 0.85 0.85 0.94 0.95 0.95 
% S2 by S1 0.81 0.83 0.84 0.85 0.86 0.88 0.87 0.95 0.96 0.97 
pCNVbaf<0.05 
# S1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.01 0.01 
# S2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
% S1 by S2 NA NA NA NA NA NA NA 0.50 1.00 1.00 
% S2 by S1 NA NA NA NA NA NA NA NA NA NA 
pCNV<0.05 or 
pCNVlrr<0.05 
# S1 9.75 8.90 8.52 8.21 8.82 8.33 8.16 8.93 8.33 7.93 
# S2 9.64 8.97 8.66 8.41 8.70 8.27 8.17 9.01 8.29 7.90 
% S1 by S2 0.78 0.78 0.80 0.81 0.83 0.85 0.85 0.94 0.95 0.95 
% S2 by S1 0.81 0.83 0.84 0.85 0.86 0.88 0.87 0.95 0.96 0.97 
pCNV<0.05 or 
pCNVbaf<0.05 
# S1 8.84 8.13 7.90 7.58 8.31 7.92 7.77 7.92 7.59 7.33 
# S2 8.57 8.01 7.80 7.57 8.12 7.79 7.67 7.50 7.29 7.06 
% S1 by S2 0.81 0.82 0.83 0.84 0.85 0.86 0.87 0.95 0.96 0.96 
% S2 by S1 0.84 0.86 0.87 0.87 0.87 0.89 0.89 0.97 0.97 0.97 
pCNVlrr<0.05 or 
pCNVbaf<0.05 
# S1 9.75 8.90 8.52 8.21 8.82 8.33 8.16 8.94 8.34 7.94 
# S2 9.64 8.97 8.66 8.41 8.70 8.27 8.17 9.01 8.29 7.90 
% S1 by S2 0.78 0.78 0.80 0.81 0.83 0.85 0.85 0.94 0.95 0.95 




# S1 9.75 8.90 8.52 8.21 8.82 8.33 8.16 8.94 8.34 7.94 
# S2 9.64 8.97 8.66 8.41 8.70 8.27 8.17 9.01 8.29 7.90 
% S1 by S2 0.78 0.78 0.80 0.81 0.83 0.85 0.85 0.94 0.95 0.95 
% S2 by S1 0.81 0.83 0.84 0.85 0.86 0.88 0.87 0.95 0.96 0.97 
 























Affymetrix Short Duplications (<100 kb) 












# S1 6.20 5.10 4.68 2.22 5.69 4.65 2.34 2.69 1.54 1.39 
# S2 6.42 5.01 4.70 2.17 5.77 4.66 2.63 2.70 1.51 1.30 
% S1 by S2 0.69 0.65 0.67 0.71 0.73 0.77 0.79 0.80 0.90 0.91 
% S2 by S1 0.66 0.68 0.70 0.72 0.71 0.73 0.75 0.77 0.95 0.97 
pCNV<0.05 
# S1 1.01 0.90 0.85 0.78 0.97 0.91 0.82 0.79 0.74 0.72 
# S2 0.90 0.88 0.83 0.77 0.89 0.83 0.77 0.65 0.63 0.63 
% S1 by S2 0.76 0.80 0.81 0.84 0.80 0.82 0.84 0.89 0.91 0.93 
% S2 by S1 0.85 0.82 0.82 0.80 0.90 0.90 0.92 0.93 0.93 0.93 
pCNVlrr<0.05 
# S1 4.53 3.93 3.70 1.63 4.37 3.79 1.70 1.31 1.19 1.16 
# S2 4.53 3.81 3.67 1.60 4.33 3.75 1.85 1.23 1.14 1.06 
% S1 by S2 0.69 0.67 0.67 0.73 0.73 0.76 0.78 0.89 0.91 0.91 
% S2 by S1 0.66 0.68 0.69 0.68 0.72 0.75 0.73 0.93 0.94 0.95 
pCNVbaf<0.05 
# S1 0.57 0.52 0.50 0.45 0.52 0.49 0.45 0.47 0.43 0.43 
# S2 0.50 0.50 0.47 0.45 0.47 0.45 0.44 0.44 0.43 0.43 
% S1 by S2 0.88 0.84 0.83 0.89 0.87 0.88 0.88 0.91 0.92 0.94 
% S2 by S1 0.91 0.81 0.81 0.81 0.94 0.94 0.94 0.96 0.96 0.96 
pCNV<0.05 or 
pCNVlrr<0.05 
# S1 4.70 4.06 3.79 1.74 4.50 3.90 1.81 1.45 1.31 1.26 
# S2 4.67 3.95 3.80 1.72 4.46 3.87 1.97 1.34 1.24 1.16 
% S1 by S2 0.70 0.67 0.68 0.74 0.74 0.76 0.79 0.89 0.91 0.92 
% S2 by S1 0.68 0.68 0.69 0.69 0.74 0.76 0.75 0.94 0.95 0.96 
pCNV<0.05 or 
pCNVbaf<0.05 
# S1 1.03 0.92 0.87 0.79 0.98 0.93 0.83 0.79 0.74 0.72 
# S2 0.93 0.90 0.84 0.77 0.90 0.83 0.78 0.65 0.63 0.63 
% S1 by S2 0.75 0.80 0.81 0.84 0.80 0.82 0.84 0.89 0.91 0.93 
% S2 by S1 0.85 0.82 0.82 0.80 0.90 0.90 0.92 0.93 0.93 0.93 
pCNVlrr<0.05 or 
pCNVbaf<0.05 
# S1 4.70 4.06 3.81 1.74 4.50 3.90 1.80 1.43 1.30 1.24 
# S2 4.69 3.96 3.80 1.71 4.46 3.86 1.97 1.33 1.23 1.15 
% S1 by S2 0.70 0.68 0.68 0.75 0.74 0.77 0.79 0.89 0.91 0.92 




# S1 4.73 4.08 3.81 1.75 4.51 3.91 1.82 1.45 1.31 1.26 
# S2 4.70 3.97 3.81 1.72 4.47 3.87 1.98 1.34 1.24 1.16 
% S1 by S2 0.70 0.67 0.68 0.74 0.74 0.77 0.79 0.89 0.91 0.92 
% S2 by S1 0.68 0.68 0.69 0.69 0.74 0.76 0.75 0.94 0.95 0.96 
 
























Affymetrix All Short CNVs (<100 kb) 
CNVision PennCNV PennCNV + QuantiSNP 
PennCNV 










# S1 16.55 14.38 13.50 10.78 14.96 13.24 10.85 19.21 10.86 9.95 
# S2 16.67 14.37 13.63 10.90 14.86 13.11 11.11 19.50 10.87 9.87 
% S1 by S2 0.74 0.73 0.75 0.78 0.79 0.82 0.84 0.90 0.95 0.95 
% S2 by S1 0.74 0.76 0.78 0.81 0.79 0.82 0.84 0.90 0.95 0.96 
pCNV<0.05 
# S1 9.85 9.03 8.75 8.37 9.28 8.83 8.58 8.70 8.32 8.04 
# S2 9.47 8.89 8.63 8.33 9.01 8.63 8.44 8.15 7.92 7.70 
% S1 by S2 0.81 0.82 0.83 0.84 0.84 0.86 0.86 0.94 0.96 0.96 
% S2 by S1 0.84 0.85 0.86 0.87 0.88 0.89 0.89 0.96 0.96 0.97 
pCNVlrr<0.05 
# S1 14.28 12.83 12.22 9.84 13.18 12.12 9.85 10.24 9.52 9.09 
# S2 14.17 12.77 12.33 10.01 13.03 12.02 10.03 10.24 9.43 8.96 
% S1 by S2 0.75 0.75 0.76 0.80 0.79 0.81 0.83 0.93 0.95 0.95 
% S2 by S1 0.76 0.78 0.79 0.83 0.81 0.83 0.85 0.95 0.96 0.96 
pCNVbaf<0.05 
# S1 0.57 0.52 0.50 0.45 0.52 0.49 0.45 0.49 0.44 0.43 
# S2 0.50 0.50 0.47 0.45 0.47 0.45 0.44 0.44 0.43 0.43 
% S1 by S2 0.88 0.84 0.83 0.89 0.87 0.88 0.88 0.89 0.92 0.94 
% S2 by S1 0.91 0.81 0.81 0.81 0.94 0.94 0.94 0.96 0.96 0.96 
pCNV<0.05 or 
pCNVlrr<0.05 
# S1 14.45 12.97 12.31 9.95 13.31 12.23 9.97 10.38 9.64 9.19 
# S2 14.31 12.91 12.46 10.13 13.16 12.14 10.15 10.35 9.53 9.05 
% S1 by S2 0.75 0.75 0.76 0.80 0.80 0.82 0.84 0.94 0.95 0.95 
% S2 by S1 0.76 0.78 0.79 0.82 0.81 0.83 0.85 0.95 0.96 0.96 
pCNV<0.05 or 
pCNVbaf<0.05 
# S1 9.88 9.05 8.77 8.37 9.30 8.85 8.59 8.71 8.33 8.05 
# S2 9.50 8.90 8.64 8.33 9.02 8.63 8.45 8.15 7.92 7.70 
% S1 by S2 0.81 0.82 0.83 0.84 0.84 0.86 0.86 0.94 0.96 0.96 
% S2 by S1 0.84 0.85 0.86 0.87 0.88 0.89 0.89 0.96 0.96 0.97 
pCNVlrr<0.05 or 
pCNVbaf<0.05 
# S1 14.45 12.97 12.33 9.95 13.31 12.23 9.96 10.37 9.63 9.18 
# S2 14.33 12.92 12.46 10.12 13.16 12.13 10.15 10.34 9.52 9.04 
% S1 by S2 0.75 0.75 0.76 0.80 0.80 0.82 0.84 0.94 0.95 0.95 




# S1 14.48 12.98 12.33 9.96 13.33 12.24 9.97 10.39 9.65 9.20 
# S2 14.34 12.93 12.47 10.13 13.17 12.14 10.16 10.35 9.53 9.05 
% S1 by S2 0.75 0.75 0.76 0.80 0.80 0.82 0.84 0.94 0.95 0.95 
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Affymetrix Long Deletions (>100 kb) 












# S1 2.14 2.07 1.96 1.84 1.85 1.81 1.67 3.58 1.80 1.85 
# S2 2.12 2.08 1.96 1.83 1.91 1.90 1.68 3.65 1.82 1.85 
% S1 by S2 0.84 0.88 0.90 0.91 0.90 0.90 0.91 0.93 0.95 0.96 
% S2 by S1 0.85 0.87 0.89 0.90 0.90 0.89 0.91 0.90 0.94 0.95 
pCNV<0.05 
# S1 1.67 1.60 1.56 1.48 1.52 1.51 1.39 1.37 1.32 1.36 
# S2 1.58 1.54 1.50 1.42 1.53 1.53 1.40 1.43 1.40 1.43 
% S1 by S2 0.92 0.97 0.97 0.98 0.93 0.93 0.94 0.99 0.99 0.99 
% S2 by S1 0.91 0.94 0.95 0.97 0.95 0.95 0.97 0.99 0.99 0.99 
pCNVlrr<0.05 
# S1 1.92 1.82 1.74 1.67 1.66 1.65 1.52 1.61 1.52 1.57 
# S2 1.92 1.89 1.81 1.70 1.77 1.77 1.59 1.74 1.61 1.67 
% S1 by S2 0.87 0.92 0.93 0.94 0.91 0.91 0.92 0.97 0.99 0.98 
% S2 by S1 0.89 0.90 0.91 0.93 0.90 0.90 0.92 0.98 0.98 0.98 
pCNVbaf<0.05 
# S1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
# S2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 
% S1 by S2 NA NA NA NA NA NA NA NA NA NA 
% S2 by S1 NA NA NA NA NA NA NA NA NA NA 
pCNV<0.05 or 
pCNVlrr<0.05 
# S1 1.92 1.82 1.74 1.67 1.66 1.65 1.52 1.61 1.52 1.57 
# S2 1.92 1.89 1.81 1.70 1.77 1.77 1.59 1.74 1.61 1.67 
% S1 by S2 0.87 0.92 0.93 0.94 0.91 0.91 0.92 0.97 0.99 0.98 
% S2 by S1 0.89 0.90 0.91 0.93 0.90 0.90 0.92 0.98 0.98 0.98 
pCNV<0.05 or 
pCNVbaf<0.05 
# S1 1.67 1.60 1.56 1.48 1.52 1.51 1.39 1.37 1.32 1.36 
# S2 1.58 1.54 1.50 1.42 1.53 1.53 1.40 1.43 1.40 1.43 
% S1 by S2 0.92 0.97 0.97 0.98 0.93 0.93 0.94 0.99 0.99 0.99 
% S2 by S1 0.91 0.94 0.95 0.97 0.95 0.95 0.97 0.99 0.99 0.99 
pCNVlrr<0.05 or 
pCNVbaf<0.05 
# S1 1.92 1.82 1.74 1.67 1.66 1.65 1.52 1.61 1.52 1.57 
# S2 1.92 1.89 1.81 1.70 1.77 1.77 1.59 1.74 1.61 1.67 
% S1 by S2 0.87 0.92 0.93 0.94 0.91 0.91 0.92 0.97 0.99 0.98 




# S1 1.92 1.82 1.74 1.67 1.66 1.65 1.52 1.61 1.52 1.57 
# S2 1.92 1.89 1.81 1.70 1.77 1.77 1.59 1.74 1.61 1.67 
% S1 by S2 0.87 0.92 0.93 0.94 0.91 0.91 0.92 0.97 0.99 0.98 
% S2 by S1 0.89 0.90 0.91 0.93 0.90 0.90 0.92 0.98 0.98 0.98 
 























Affymetrix Long Duplications (>100 kb) 












# S1 3.23 3.17 2.74 1.93 2.70 2.62 1.70 2.99 1.46 1.58 
# S2 3.57 3.56 3.17 2.19 2.98 2.85 1.83 3.10 1.62 1.71 
% S1 by S2 0.75 0.81 0.86 0.87 0.83 0.84 0.88 0.83 0.93 0.93 
% S2 by S1 0.73 0.75 0.79 0.78 0.77 0.80 0.81 0.80 0.92 0.92 
pCNV<0.05 
# S1 0.76 0.74 0.74 0.69 0.75 0.75 0.69 0.63 0.63 0.63 
# S2 0.77 0.75 0.75 0.65 0.75 0.75 0.66 0.62 0.62 0.62 
% S1 by S2 0.95 0.97 0.97 0.97 0.98 0.98 0.97 1.00 1.00 1.00 
% S2 by S1 0.94 0.96 0.96 1.00 0.96 0.96 0.98 1.00 1.00 1.00 
pCNVlrr<0.05 
# S1 2.16 2.25 2.06 1.37 2.02 2.01 1.28 1.15 1.09 1.12 
# S2 2.25 2.26 2.20 1.37 2.17 2.13 1.33 1.12 1.12 1.12 
% S1 by S2 0.83 0.87 0.89 0.90 0.86 0.86 0.89 0.97 0.97 0.97 
% S2 by S1 0.83 0.86 0.87 0.87 0.82 0.84 0.86 0.92 0.92 0.92 
pCNVbaf<0.05 
# S1 0.44 0.45 0.44 0.44 0.45 0.45 0.44 0.43 0.42 0.43 
# S2 0.44 0.43 0.43 0.43 0.42 0.42 0.41 0.41 0.40 0.41 
% S1 by S2 0.95 1.00 1.00 1.00 0.95 0.95 0.95 1.00 1.00 1.00 
% S2 by S1 0.96 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
pCNV<0.05 or 
pCNVlrr<0.05 
# S1 2.23 2.32 2.13 1.44 2.09 2.08 1.35 1.22 1.16 1.19 
# S2 2.35 2.36 2.30 1.47 2.25 2.22 1.42 1.22 1.22 1.22 
% S1 by S2 0.83 0.87 0.90 0.91 0.86 0.86 0.89 0.97 0.98 0.98 
% S2 by S1 0.84 0.86 0.87 0.88 0.83 0.84 0.87 0.93 0.93 0.93 
pCNV<0.05 or 
pCNVbaf<0.05 
# S1 0.77 0.77 0.76 0.71 0.77 0.77 0.70 0.65 0.64 0.65 
# S2 0.78 0.77 0.76 0.67 0.75 0.75 0.66 0.63 0.63 0.63 
% S1 by S2 0.93 0.97 0.97 0.97 0.98 0.98 0.97 1.00 1.00 1.00 
% S2 by S1 0.94 0.96 0.96 1.00 0.96 0.96 0.98 1.00 1.00 1.00 
pCNVlrr<0.05 or 
pCNVbaf<0.05 
# S1 2.24 2.35 2.15 1.47 2.10 2.10 1.37 1.23 1.17 1.21 
# S2 2.36 2.37 2.30 1.48 2.25 2.22 1.42 1.23 1.23 1.23 
% S1 by S2 0.83 0.88 0.90 0.91 0.86 0.86 0.89 0.97 0.98 0.98 




# S1 2.24 2.35 2.15 1.47 2.10 2.10 1.37 1.23 1.17 1.21 
# S2 2.37 2.37 2.30 1.49 2.25 2.22 1.42 1.23 1.23 1.23 
% S1 by S2 0.83 0.88 0.90 0.91 0.86 0.86 0.89 0.97 0.98 0.98 
% S2 by S1 0.84 0.86 0.87 0.88 0.83 0.84 0.87 0.93 0.93 0.93 
 

























Affymetrix All Long CNVs (>100 kb) 
CNVision PennCNV PennCNV + QuantiSNP 
PennCNV 










# S1 5.37 5.24 4.70 3.77 4.56 4.43 3.37 6.57 3.26 3.43 
# S2 5.69 5.63 5.13 4.02 4.90 4.75 3.50 6.76 3.43 3.57 
% S1 by S2 0.79 0.83 0.87 0.89 0.86 0.87 0.90 0.88 0.93 0.94 
% S2 by S1 0.75 0.78 0.81 0.82 0.81 0.83 0.86 0.85 0.92 0.93 
pCNV<0.05 
# S1 2.43 2.34 2.30 2.17 2.27 2.26 2.08 2.00 1.96 1.99 
# S2 2.35 2.29 2.24 2.07 2.28 2.28 2.06 2.05 2.02 2.05 
% S1 by S2 0.92 0.97 0.97 0.97 0.94 0.94 0.95 0.99 0.99 0.99 
% S2 by S1 0.92 0.94 0.95 0.98 0.96 0.96 0.98 0.99 0.99 0.99 
pCNVlrr<0.05 
# S1 4.08 4.07 3.80 3.04 3.68 3.66 2.80 2.76 2.61 2.69 
# S2 4.17 4.15 4.01 3.08 3.94 3.90 2.92 2.86 2.73 2.79 
% S1 by S2 0.85 0.89 0.91 0.93 0.89 0.90 0.92 0.97 0.98 0.97 
% S2 by S1 0.85 0.86 0.86 0.89 0.84 0.85 0.89 0.96 0.96 0.96 
pCNVbaf<0.05 
# S1 0.44 0.45 0.44 0.44 0.45 0.45 0.44 0.43 0.42 0.43 
# S2 0.44 0.43 0.43 0.43 0.42 0.42 0.41 0.41 0.40 0.41 
% S1 by S2 0.95 1.00 1.00 1.00 0.95 0.95 0.95 1.00 1.00 1.00 
% S2 by S1 0.96 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
pCNV<0.05 or 
pCNVlrr<0.05 
# S1 4.15 4.14 3.87 3.11 3.75 3.73 2.87 2.83 2.68 2.76 
# S2 4.27 4.24 4.10 3.17 4.03 3.98 3.01 2.96 2.83 2.89 
% S1 by S2 0.85 0.89 0.91 0.93 0.90 0.90 0.92 0.97 0.98 0.97 
% S2 by S1 0.85 0.86 0.87 0.90 0.85 0.86 0.89 0.96 0.96 0.96 
pCNV<0.05 or 
pCNVbaf<0.05 
# S1 2.44 2.37 2.31 2.19 2.29 2.28 2.10 2.02 1.97 2.01 
# S2 2.37 2.30 2.25 2.09 2.28 2.28 2.06 2.07 2.03 2.07 
% S1 by S2 0.91 0.97 0.97 0.97 0.94 0.94 0.95 0.99 0.99 0.99 
% S2 by S1 0.92 0.94 0.95 0.98 0.96 0.96 0.98 0.99 0.99 0.99 
pCNVlrr<0.05 or 
pCNVbaf<0.05 
# S1 4.17 4.17 3.89 3.14 3.77 3.75 2.89 2.84 2.69 2.77 
# S2 4.28 4.25 4.10 3.18 4.03 3.98 3.01 2.97 2.83 2.90 
% S1 by S2 0.85 0.90 0.91 0.93 0.90 0.90 0.92 0.97 0.98 0.97 




# S1 4.17 4.17 3.89 3.14 3.77 3.75 2.89 2.84 2.69 2.77 
# S2 4.29 4.26 4.11 3.19 4.03 3.98 3.01 2.97 2.83 2.90 
% S1 by S2 0.85 0.90 0.91 0.93 0.90 0.90 0.92 0.97 0.98 0.97 
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# S1 6.30 5.70 4.90 4.05 4.85 4.95 4.10 3.40 2.90 3.75 1.35 1.60 1.50 1.15 1.10 
# S2 6.00 5.45 4.60 4.00 4.70 4.85 4.10 3.35 2.95 3.60 1.15 1.35 1.25 1.05 1.10 
% S1 by S2 0.87 0.89 0.94 0.98 0.95 0.95 0.95 1.00 1.00 0.97 0.57 0.67 0.79 0.90 0.83 
% S2 by S1 0.89 0.86 0.93 0.95 0.93 0.94 0.88 0.93 0.94 0.92 0.72 0.79 0.92 1.00 0.92 
pCNV < 0.05 
# S1 3.90 3.75 3.45 3.05 3.65 3.15 2.95 2.60 2.25 2.90 0.75 0.80 0.85 0.80 0.75 
# S2 3.90 3.60 3.50 3.10 3.55 3.10 2.65 2.45 2.15 2.60 0.80 0.95 1.05 0.95 0.95 
% S1 by S2 0.96 0.92 1.00 1.00 0.93 0.99 0.93 1.00 1.00 0.93 0.82 0.91 1.00 1.00 1.00 
% S2 by S1 0.97 0.95 0.98 0.99 0.95 1.00 0.94 0.97 0.99 0.94 0.86 1.00 1.00 1.00 1.00 
pCNVlrr < 0.05 
# S1 4.80 4.40 3.80 3.25 3.95 3.65 3.30 2.90 2.50 3.25 1.15 1.10 0.90 0.75 0.70 
# S2 4.65 4.15 3.75 3.20 3.85 3.60 3.15 2.85 2.45 3.05 1.05 1.00 0.90 0.75 0.80 
% S1 by S2 0.91 0.90 0.96 0.97 0.95 0.99 0.96 1.00 1.00 0.96 0.60 0.65 0.78 0.80 0.89 
% S2 by S1 0.90 0.87 0.97 0.99 0.92 0.95 0.88 0.97 0.99 0.91 0.80 0.85 0.91 1.00 1.00 
pCNVbaf < 0.05 
# S1 0.60 0.65 0.75 0.70 0.65 0.00 0.00 0.00 0.00 0.00 0.60 0.65 0.75 0.70 0.65 
# S2 0.70 0.85 0.95 0.85 0.85 0.00 0.00 0.00 0.00 0.00 0.70 0.85 0.95 0.85 0.85 
% S1 by S2 0.89 1.00 1.00 1.00 1.00 NA NA NA NA NA 0.89 1.00 1.00 1.00 1.00 
% S2 by S1 0.83 1.00 1.00 1.00 1.00 NA NA NA NA NA 0.83 1.00 1.00 1.00 1.00 
pCNV < 0.05 or 
pCNVlrr < 0.05 
# S1 4.90 4.60 4.05 3.45 4.15 3.65 3.30 2.90 2.50 3.25 1.25 1.30 1.15 0.95 0.90 
# S2 4.70 4.30 4.00 3.40 4.00 3.60 3.15 2.85 2.45 3.05 1.10 1.15 1.15 0.95 0.95 
% S1 by S2 0.91 0.90 0.96 0.97 0.95 0.99 0.96 1.00 1.00 0.96 0.63 0.72 0.83 0.86 0.91 
% S2 by S1 0.90 0.88 0.97 0.99 0.93 0.95 0.88 0.97 0.99 0.91 0.74 0.87 0.92 1.00 1.00 
pCNV < 0.05 or 
pCNVbaf < 0.05 
# S1 3.90 3.75 3.45 3.05 3.65 3.15 2.95 2.60 2.25 2.90 0.75 0.80 0.85 0.80 0.75 
# S2 3.90 3.60 3.50 3.10 3.55 3.10 2.65 2.45 2.15 2.60 0.80 0.95 1.05 0.95 0.95 
% S1 by S2 0.96 0.92 1.00 1.00 0.93 0.99 0.93 1.00 1.00 0.93 0.82 0.91 1.00 1.00 1.00 
% S2 by S1 0.97 0.95 0.98 0.99 0.95 1.00 0.94 0.97 0.99 0.94 0.86 1.00 1.00 1.00 1.00 
pCNVlrr < 0.05 
or pCNVbaf < 
0.05 
# S1 4.90 4.60 4.05 3.45 4.15 3.65 3.30 2.90 2.50 3.25 1.25 1.30 1.15 0.95 0.90 
# S2 4.70 4.30 4.00 3.40 4.00 3.60 3.15 2.85 2.45 3.05 1.10 1.15 1.15 0.95 0.95 
% S1 by S2 0.91 0.90 0.96 0.97 0.95 0.99 0.96 1.00 1.00 0.96 0.63 0.72 0.83 0.86 0.91 
% S2 by S1 0.90 0.88 0.97 0.99 0.93 0.95 0.88 0.97 0.99 0.91 0.74 0.87 0.92 1.00 1.00 
pCNV < 0.05 or 
pCNVlrr < 0.05 
or pCNVbaf < 
0.05 
# S1 4.90 4.60 4.05 3.45 4.15 3.65 3.30 2.90 2.50 3.25 1.25 1.30 1.15 0.95 0.90 
# S2 4.70 4.30 4.00 3.40 4.00 3.60 3.15 2.85 2.45 3.05 1.10 1.15 1.15 0.95 0.95 
% S1 by S2 0.90 0.91 0.96 0.97 0.95 0.99 0.96 1.00 1.00 0.96 0.63 0.69 0.83 0.86 0.91 
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# S1 2.65 2.00 3.20 2.10 1.85 1.45 0.90 1.20 0.90 0.85 1.20 1.10 2.00 1.20 1.00 
# S2 2.70 2.15 3.20 2.00 2.05 1.50 1.15 1.20 1.00 1.15 1.20 1.00 2.00 1.00 0.90 
% S1 by S2 0.83 0.79 0.81 0.93 0.83 0.95 0.92 1.00 1.00 1.00 0.68 0.68 0.69 0.89 0.73 
% S2 by S1 0.82 0.86 0.92 0.99 0.91 0.85 0.87 1.00 1.00 0.87 0.73 0.88 0.85 0.97 0.95 
pCNV < 0.05 
# S1 2.25 1.75 2.15 1.90 1.70 1.35 0.90 1.05 0.90 0.85 0.90 0.85 1.10 1.00 0.85 
# S2 2.15 1.80 2.00 1.85 1.80 1.25 0.95 1.00 0.95 0.95 0.90 0.85 1.00 0.90 0.85 
% S1 by S2 0.89 0.84 0.93 0.95 0.86 0.97 0.92 1.00 1.00 1.00 0.77 0.77 0.88 0.92 0.77 
% S2 by S1 0.92 0.92 0.99 0.99 0.92 1.00 0.86 1.00 1.00 0.86 0.83 0.95 0.97 0.97 0.95 
pCNVlrr < 0.05 
# S1 2.35 1.80 2.55 1.85 1.70 1.40 0.90 1.15 0.90 0.85 0.95 0.90 1.40 0.95 0.85 
# S2 2.15 1.70 2.55 1.70 1.70 1.30 1.00 1.10 0.95 1.00 0.85 0.70 1.45 0.75 0.70 
% S1 by S2 0.84 0.80 0.89 0.95 0.83 0.95 0.92 1.00 1.00 1.00 0.63 0.63 0.83 0.92 0.68 
% S2 by S1 0.93 0.90 0.94 0.98 0.90 0.98 0.86 1.00 1.00 0.86 0.75 0.94 0.87 0.96 0.94 
pCNVbaf < 0.05 
# S1 0.70 0.70 0.90 0.80 0.70 0.00 0.00 0.00 0.00 0.00 0.70 0.70 0.90 0.80 0.70 
# S2 0.80 0.75 0.85 0.75 0.75 0.00 0.00 0.00 0.00 0.00 0.80 0.75 0.85 0.75 0.75 
% S1 by S2 0.90 0.90 0.96 1.00 0.90 NA NA NA NA NA 0.90 0.90 0.96 1.00 0.90 
% S2 by S1 0.86 1.00 1.00 1.00 1.00 NA NA NA NA NA 0.86 1.00 1.00 1.00 1.00 
pCNV < 0.05 or 
pCNVlrr < 0.05 
# S1 2.45 1.90 2.75 2.00 1.80 1.40 0.90 1.15 0.90 0.85 1.05 1.00 1.60 1.10 0.95 
# S2 2.40 1.90 2.80 1.95 1.90 1.30 1.00 1.10 0.95 1.00 1.10 0.90 1.70 1.00 0.90 
% S1 by S2 0.84 0.80 0.87 0.95 0.83 0.95 0.92 1.00 1.00 1.00 0.67 0.67 0.82 0.93 0.71 
% S2 by S1 0.88 0.91 0.94 0.99 0.91 0.98 0.86 1.00 1.00 0.86 0.73 0.95 0.89 0.97 0.95 
pCNV < 0.05 or 
pCNVbaf < 0.05 
# S1 2.25 1.75 2.15 1.90 1.70 1.35 0.90 1.05 0.90 0.85 0.90 0.85 1.10 1.00 0.85 
# S2 2.15 1.80 2.05 1.85 1.80 1.25 0.95 1.00 0.95 0.95 0.90 0.85 1.05 0.90 0.85 
% S1 by S2 0.89 0.84 0.93 0.95 0.86 0.97 0.92 1.00 1.00 1.00 0.77 0.77 0.88 0.92 0.77 
% S2 by S1 0.92 0.92 0.99 0.99 0.92 1.00 0.86 1.00 1.00 0.86 0.83 0.95 0.97 0.97 0.95 
pCNVlrr < 0.05 
or pCNVbaf < 
0.05 
# S1 2.45 1.90 2.75 2.00 1.80 1.40 0.90 1.15 0.90 0.85 1.05 1.00 1.60 1.10 0.95 
# S2 2.40 1.90 2.85 1.95 1.90 1.30 1.00 1.10 0.95 1.00 1.10 0.90 1.75 1.00 0.90 
% S1 by S2 0.84 0.80 0.87 0.95 0.83 0.95 0.92 1.00 1.00 1.00 0.67 0.67 0.82 0.93 0.71 
% S2 by S1 0.88 0.91 0.94 0.99 0.91 0.98 0.86 1.00 1.00 0.86 0.73 0.95 0.90 0.97 0.95 
pCNV < 0.05 or 
pCNVlrr < 0.05 
or pCNVbaf < 
0.05 
# S1 2.45 1.90 2.75 2.00 1.80 1.40 0.90 1.15 0.90 0.85 1.05 1.00 1.60 1.10 0.95 
# S2 2.40 1.90 2.85 1.95 1.90 1.30 1.00 1.10 0.95 1.00 1.10 0.90 1.75 1.00 0.90 
% S1 by S2 0.83 0.82 0.87 0.94 0.88 0.95 0.91 1.00 1.00 1.00 0.64 0.64 0.82 0.92 0.77 
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CNV Tested effect 
All (<1%) Singleton CNVs > 500 kb CNVs > 1 Mb CNVs 
Cases Controls p value Cases Controls p value Cases Controls p value Cases Controls p value 
Long (> 
100 kb or 
longer) 
All CNVs/subj 0.3242 0.3181 1.82E-01 0.0559 0.0501 8.10E-02 0.0216 0.0189 2.06E-01 0.0066 0.0044 9.41E-02 Subjs w CNV 0.2818 0.2709 4.49E-02 0.0547 0.0485 6.59E-02 0.0215 0.0186 1.90E-01 0.0066 0.0044 9.41E-02 
Intergenic CNVs/subj 0.1337 0.1376 6.31E-01 0.0206 0.0180 1.09E-01 0.0028 0.0020 3.97E-01 0.0010 0.0003 1.16E-01 Subjs w CNV 0.1247 0.1298 7.16E-01 0.0204 0.0178 1.15E-01 0.0028 0.0020 3.97E-01 0.0010 0.0003 1.16E-01 
Gene-
containing 
CNVs/subj 0.1905 0.1805 7.12E-02 0.0420 0.0376 1.38E-01 0.0189 0.0169 2.39E-01 0.0055 0.0041 1.99E-01 
Subjs w CNV 0.1773 0.1628 1.05E-02 0.0412 0.0370 1.52E-01 0.0189 0.0166 2.00E-01 0.0055 0.0041 1.99E-01 
Genes/CNV 0.7183 0.7074 3.75E-01 0.1294 0.1420 7.78E-01 0.2097 0.1656 1.08E-01 0.0931 0.0457 4.65E-02 
Genes/CNV kb 0.0099 0.0098 5.26E-01 0.0120 0.0131 8.92E-01 0.0113 0.0116 3.72E-01 0.0100 0.0079 1.66E-01 
Exon-
containing 
CNVs/subj 0.1754 0.1683 1.04E-01 0.0410 0.0364 1.14E-01 0.0189 0.0169 2.42E-01 0.0055 0.0041 1.98E-01 
Subjs w CNV 0.1635 0.1532 3.00E-02 0.0403 0.0358 1.20E-01 0.0189 0.0166 2.04E-01 0.0055 0.0041 1.98E-01 
Genes/CNV 3.8760 3.6940 2.74E-01 0.6983 0.7495 7.04E-01 1.3940 1.0450 6.54E-02 0.6121 0.3052 5.56E-02 
Genes/CNV kb 0.0477 0.0468 4.62E-01 0.0586 0.0673 9.18E-01 0.0742 0.0727 2.58E-01 0.0639 0.0525 2.02E-01 




CNVs/subj 1.0150 0.9777 2.20E-03 0.2154 0.2009 3.30E-02         
Subjs w CNV 0.5798 0.5744 1.87E-02 0.1865 0.1719 5.35E-03         
Intergenic 
CNVs/subj 0.5062 0.4831 4.03E-03 0.1048 0.0921 6.90E-03         
Subjs w CNV 0.3692 0.3651 5.31E-02 0.0972 0.0868 1.01E-02         
Gene-
containing 
CNVs/subj 0.5087 0.4946 6.21E-02 0.1176 0.1155 3.03E-01         
Subjs w CNV 0.3791 0.3684 2.07E-02 0.1059 0.1049 3.14E-01         
Genes/CNV 0.8919 0.8518 3.55E-02 0.2109 0.1947 1.50E-01         
Genes/CNV kb 0.0281 0.0286 6.02E-01 0.0329 0.0346 6.85E-01         
Exon-
containing 
CNVs/subj 0.3299 0.3097 2.99E-02 0.0893 0.0851 2.52E-01         
Subjs w CNV 0.2697 0.2522 5.55E-03 0.0808 0.0782 3.01E-01         
Genes/CNV 2.1270 1.9440 5.15E-02 0.5422 0.5066 3.49E-01         
Genes/CNV kb 0.0558 0.0535 3.14E-01 0.0670 0.0685 7.92E-01         
Intronic 
CNVs/subj 0.1787 0.1849 4.91E-01 0.0351 0.0386 7.09E-01         
Subjs w CNV 0.1616 0.1641 3.22E-01 0.0337 0.0377 7.47E-01             
 
 

















Type of Dup Type of CNV Tested effect 
All (< 1%) Singleton CNVs > 500 kb CNVs > 1 Mb CNVs 
Cases Controls p value Cases Controls p value Cases Controls p value Cases Controls p value 
Long (> 100 
kb or longer) 
All CNVs/subj 0.4960 0.4763 1.18E-01 0.0863 0.0753 3.16E-02 0.0720 0.0712 6.49E-01 0.0161 0.0155 5.99E-01 
Subjs w CNV 0.3678 0.3630 4.09E-01 0.0779 0.0700 6.29E-02 0.0678 0.0684 7.35E-01 0.0157 0.0152 6.00E-01 
Intergenic CNVs/subj 0.0867 0.0791 9.35E-02 0.0225 0.0184 7.17E-02 0.0076 0.0066 4.14E-01 0.0012 0.0005 1.74E-01 
Subjs w CNV 0.0818 0.0747 1.06E-01 0.0218 0.0180 7.37E-02 0.0076 0.0066 4.14E-01 0.0012 0.0005 1.74E-01 
Gene-
containing 
CNVs/subj 0.4093 0.3972 2.20E-01 0.0702 0.0651 2.11E-01 0.0644 0.0646 6.92E-01 0.0149 0.0151 7.04E-01 
Subjs w CNV 0.3161 0.3129 4.32E-01 0.0633 0.0614 4.17E-01 0.0614 0.0620 7.15E-01 0.0145 0.0148 7.09E-01 
Genes/CNV 2.4920 2.5020 5.27E-01 0.2901 0.2750 4.60E-01 0.7848 0.8495 7.81E-01 0.3318 0.3714 7.38E-01 
Genes/CNV kb 0.0172 0.0181 9.41E-01 0.0161 0.0171 8.48E-01 0.0122 0.0131 6.64E-01 0.0130 0.0137 5.28E-01 
Exon-
containing 
CNVs/subj 0.4057 0.3948 2.47E-01 0.0694 0.0647 2.44E-01 0.0644 0.0646 6.91E-01 0.0149 0.0151 7.08E-01 
Subjs w CNV 0.3135 0.3118 5.08E-01 0.0628 0.0611 4.32E-01 0.0614 0.0620 7.13E-01 0.0145 0.0148 7.13E-01 
Genes/CNV 15.3200 15.0900 4.12E-01 1.6930 1.6330 5.53E-01 5.4280 5.9070 7.69E-01 2.3660 2.6810 7.37E-01 
Genes/CNV kb 0.0954 0.0961 5.93E-01 0.0889 0.0957 8.91E-01 0.0846 0.0889 5.62E-01 0.0922 0.0997 5.50E-01 
Intronic CNVs/subj 0.0036 0.0024 1.02E-01 0.0017 0.0012 2.86E-01 0.0000 0.0000 1.00E+00 0.0000 0.0000 1.00E+00 
Subjs w CNV 0.0036 0.0024 1.02E-01 0.0017 0.0012 2.86E-01 0.0000 0.0000 1.00E+00 0.0000 0.0000 1.00E+00 
Short (< 100 
kb) 
All CNVs/subj 0.6702 0.7015 7.80E-01 0.1715 0.1773 6.21E-01 
        
Subjs w CNV 0.4616 0.4582 1.24E-01 0.1517 0.1471 1.17E-01         
Intergenic CNVs/subj 0.2524 0.2655 7.32E-01 0.0706 0.0696 2.29E-01 
        
Subjs w CNV 0.2164 0.2199 3.59E-01 0.0677 0.0628 4.89E-02         
Gene-
containing 
CNVs/subj 0.4178 0.4360 7.22E-01 0.1069 0.1133 8.21E-01         
Subjs w CNV 0.3237 0.3189 1.48E-01 0.0965 0.0978 5.40E-01         
Genes/CNV 0.9334 0.9953 8.76E-01 0.2285 0.2372 6.74E-01         
Genes/CNV kb 0.0339 0.0334 4.64E-01 0.0326 0.0338 7.50E-01         
Exon-
containing 
CNVs/subj 0.3446 0.3645 8.29E-01 0.0898 0.0973 8.93E-01         
Subjs w CNV 0.2756 0.2748 3.36E-01 0.0815 0.0845 7.22E-01         
Genes/CNV 3.5150 3.6340 7.19E-01 0.8014 0.8504 7.56E-01         
Genes/CNV kb 0.1089 0.1020 1.78E-01 0.0937 0.1027 9.13E-01         
Intronic CNVs/subj 0.0732 0.0715 2.28E-01 0.0192 0.0220 8.13E-01 
        
Subjs w CNV 0.0701 0.0667 1.16E-01 0.0190 0.0217 8.09E-01             
 
Shown are results of global burden analyses of deletions and of duplications in cases vs. controls for all CNVs in each class (genic, exonic, 
intronic and intergenic CNVs) and then separately for CNVs < 100 kb and > 100 kb, with secondary analyses for singleton CNVs (occurring 
only once in this entire dataset), CNVs > 500 kb and CNVs > 1000 kb. All tests are one-sided permutations based on the assumption of 
increased CNV burden in cases. CNVs/subj, average number of CNVs per subject; Subjs w CNV, proportion of subjects with at least one 
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Type of  
CNV Tested effect 
All (<1%) Singleton CNVs >500kb CNVs >1Mb CNVs 




Sex 6.49E-01 5.86E-01 5.42E-01 4.95E-01 3.71E-01 2.04E-01 3.87E-01 1.56E-01 
Phenotype 4.84E-01 3.66E-01 1.92E-01 6.93E-01 3.55E-01 2.20E-01 1.26E-01 2.10E-01 
Batch 6.29E-07 4.66E-04 8.77E-07 3.74E-06 2.83E-01 3.92E-01 1.91E-01 1.67E-01 
Gene- 
containing 
Sex 6.76E-01 5.28E-01 2.36E-01 2.56E-01 6.91E-01 3.61E-01 5.20E-01 2.10E-01 
Phenotype 2.17E-01 2.75E-01 2.97E-01 5.53E-01 4.52E-01 3.44E-01 2.81E-01 3.68E-01 
Batch 4.69E-04 2.30E-02 1.88E-07 8.42E-08 1.44E-01 5.39E-01 2.73E-01 3.56E-01 
Exon- 
containing 
Sex 8.91E-01 6.78E-01 3.25E-01 2.58E-01 6.91E-01 3.61E-01 5.20E-01 2.10E-01 
Phenotype 3.15E-01 3.12E-01 2.50E-01 4.30E-01 4.52E-01 3.44E-01 2.81E-01 3.68E-01 
Batch 2.90E-03 5.16E-02 1.48E-07 2.08E-07 1.44E-01 5.39E-01 2.73E-01 3.56E-01 
Intronic 
Sex 4.36E-02 6.38E-02 2.09E-01 1.79E-01 NA NA NA NA 
Phenotype 3.28E-01 4.58E-01 4.94E-01 9.14E-01 NA NA NA NA 
Batch 7.73E-03 1.77E-03 2.19E-01 1.90E-01 NA NA NA NA 
Intergenic 
Sex 2.35E-01 9.63E-01 4.47E-01 6.55E-01 1.25E-01 1.85E-01 4.50E-01 4.52E-01 
Phenotype 7.10E-01 8.67E-01 2.21E-01 4.45E-01 5.17E-01 2.80E-01 1.35E-01 1.74E-01 




Sex 2.27E-04 1.91E-02 1.21E-01 7.20E-01 
  
Phenotype 2.28E-01 5.04E-02 2.25E-01 4.29E-02 
Batch 0.00E+00 1.59E-161 3.81E-68 1.82E-22 
Gene- 
containing 
Sex 5.15E-03 9.24E-03 4.41E-01 3.85E-01 
Phenotype 6.34E-01 1.64E-01 8.82E-01 2.97E-01 
Batch 1.11E-208 5.36E-69 6.77E-34 9.57E-10 
Exon- 
containing 
Sex 1.19E-03 1.22E-03 3.38E-01 4.22E-01 
Phenotype 2.41E-01 7.38E-02 6.46E-01 2.88E-01 
Batch 6.30E-120 7.74E-44 4.24E-22 1.11E-06 
Intronic 
Sex 7.66E-01 6.20E-01 7.17E-01 9.56E-01 
Phenotype 3.83E-01 7.08E-01 3.41E-01 8.23E-01 
Batch 3.41E-109 2.29E-31 4.80E-20 7.64E-06 
Intergenic 
Sex 9.42E-03 5.37E-01 1.10E-01 6.51E-01 
Phenotype 1.83E-01 1.39E-01 4.95E-02 3.70E-02 
Batch 4.67E-316 1.52E-113 2.96E-49 6.21E-18 
 























All (<1%) Singleton CNVs >500kb CNVs >1Mb CNVs 




Sex 6.80E-01 3.61E-01 5.20E-01 1.77E-01 1.34E-01 1.11E-01 3.53E-01 3.10E-01 
Phenotype 2.11E-01 4.63E-01 5.80E-02 2.48E-01 8.91E-01 8.37E-01 9.50E-01 7.03E-01 
Batch 5.58E-04 9.13E-08 1.02E-03 7.19E-04 1.86E-07 1.45E-08 1.29E-04 4.34E-05 
Gene- 
containing 
Sex 5.07E-01 4.16E-01 3.07E-01 6.86E-02 1.80E-01 2.10E-01 4.05E-01 4.58E-01 
Phenotype 4.47E-01 8.51E-01 4.01E-01 9.17E-01 7.56E-01 7.83E-01 7.96E-01 8.16E-01 
Batch 9.30E-04 6.35E-05 1.02E-02 2.52E-03 7.21E-07 1.24E-05 3.10E-03 2.18E-02 
Exon- 
containing 
Sex 5.06E-01 4.26E-01 3.59E-01 1.20E-01 1.80E-01 2.10E-01 4.05E-01 4.58E-01 
Phenotype 5.01E-01 8.67E-01 4.52E-01 9.67E-01 7.56E-01 7.83E-01 7.96E-01 8.16E-01 
Batch 1.06E-03 6.87E-05 7.90E-03 4.11E-03 7.21E-07 1.24E-05 3.10E-03 2.18E-02 
Intronic 
Sex 9.89E-01 6.67E-01 6.86E-01 5.53E-01 NA NA NA NA 
Phenotype 2.07E-01 6.31E-01 4.85E-01 4.58E-01 NA NA NA NA 
Batch 8.96E-01 7.82E-01 5.92E-01 5.93E-01 NA NA NA NA 
Intergenic 
Sex 5.70E-01 6.46E-01 7.38E-01 8.21E-01 4.54E-01 2.20E-01 6.04E-01 3.80E-01 
Phenotype 1.15E-01 1.09E-01 1.28E-01 2.44E-01 6.10E-01 1.90E-01 1.58E-01 1.06E-01 




Sex 3.77E-01 1.78E-01 2.73E-01 3.59E-01 
  
Phenotype 1.29E-01 2.66E-01 6.41E-01 9.75E-01 
Batch 1.01E-160 1.31E-57 3.90E-31 2.94E-12 
Gene- 
containing 
Sex 3.68E-01 2.64E-01 9.79E-01 9.75E-01 
Phenotype 2.70E-01 5.89E-01 3.27E-01 7.49E-01 
Batch 1.15E-89 2.44E-27 1.42E-20 5.05E-07 
Exon- 
containing 
Sex 4.68E-01 3.38E-01 6.01E-01 7.24E-01 
Phenotype 1.61E-01 4.40E-01 1.80E-01 5.15E-01 
Batch 5.74E-77 1.72E-24 1.78E-18 2.98E-06 
Intronic 
Sex 4.76E-01 3.95E-01 1.41E-01 2.43E-01 
Phenotype 6.33E-01 4.40E-01 4.09E-01 5.49E-01 
Batch 1.11E-26 1.47E-08 7.18E-03 3.04E-01 
Intergenic 
Sex 7.17E-01 3.89E-01 9.45E-02 1.15E-01 
Phenotype 2.03E-01 1.72E-01 6.02E-01 5.31E-01 
Batch 4.39E-110 4.36E-46 2.13E-16 1.62E-07 
 
Shown are results of multiple linear regressions to evaluate the potential confounding effect by using total CNV number or length as dependent 
variable and case/control status, batch, and sex as independent variables. Analyses were conducted separately for deletions and duplications, 
for longer and shorter (<100kb) CNVs, for all CNVs, and those overlapping with at least one gene, and those overlapping with at least one 
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Del Type of CNV Tested effect 
All (< 1%) Singleton CNVs > 500 kb CNVs > 1 Mb CNVs 






CNVs/subj 0.3283 0.3101 1.00E-01 0.0829 0.0768 2.03E-01 0.0225 0.0210 3.68E-01 0.0062 0.0049 3.07E-01 
Subjs w CNV 0.2851 0.2626 2.27E-02 0.0798 0.0728 1.51E-01 0.0222 0.0207 3.67E-01 0.0062 0.0049 3.07E-01 
Intergenic CNVs/subj 0.1332 0.1338 5.42E-01 0.0324 0.0296 2.88E-01 0.0022 0.0025 6.96E-01 0.0012 0.0000 6.30E-02 
Subjs w CNV 0.1245 0.1270 6.34E-01 0.0321 0.0287 2.35E-01 0.0022 0.0025 6.96E-01 0.0012 0.0000 6.30E-02 
Gene-
containing 
CNVs/subj 0.1951 0.1763 4.16E-02 0.0604 0.0536 1.38E-01 0.0204 0.0185 3.28E-01 0.0049 0.0049 5.69E-01 
Subjs w CNV 0.1809 0.1600 1.37E-02 0.0586 0.0524 1.53E-01 0.0204 0.0182 2.93E-01 0.0049 0.0049 5.69E-01 
Genes/CNV 0.7793 0.7226 2.38E-01 0.1637 0.1936 8.28E-01 0.2549 0.1899 1.54E-01 0.1174 0.0647 1.26E-01 
Genes/CNV kb 0.0102 0.0097 2.14E-01 0.0103 0.0106 6.00E-01 0.0131 0.0119 3.33E-01 0.0131 0.0098 1.87E-01 
Exon-
containing 
CNVs/subj 0.1825 0.1649 4.75E-02 0.0583 0.0515 1.31E-01 0.0204 0.0185 3.25E-01 0.0049 0.0049 5.71E-01 
Subjs w CNV 0.1699 0.1510 2.15E-02 0.0570 0.0506 1.35E-01 0.0204 0.0182 2.91E-01 0.0049 0.0049 5.71E-01 
Genes/CNV 4.2240 3.7410 1.80E-01 0.9041 0.9439 5.91E-01 1.6740 1.1740 1.24E-01 0.7380 0.4405 1.82E-01 
Genes/CNV kb 0.0493 0.0453 1.78E-01 0.0519 0.0520 5.00E-01 0.0856 0.0711 2.25E-01 0.0797 0.0663 3.20E-01 
Intronic CNVs/subj 0.0126 0.0114 3.70E-01 0.0049 0.0052 6.34E-01 0.0000 0.0000 1.00E+00 0.0000 0.0000 1.00E+00 
Subjs w CNV 0.0126 0.0108 2.81E-01 0.0049 0.0052 6.34E-01 0.0000 0.0000 1.00E+00 0.0000 0.0000 1.00E+00 
Short (< 
100 kb) 
All CNVs/subj 0.9846 0.9202 8.95E-03 0.2965 0.2700 6.13E-02       Subjs w CNV 0.5746 0.5524 2.81E-02 0.2432 0.2260 4.86E-02       
Intergenic CNVs/subj 0.4867 0.4562 3.77E-02 0.1430 0.1292 7.23E-02       Subjs w CNV 0.3634 0.3471 7.40E-02 0.1307 0.1190 7.92E-02       
Gene-
containing 
CNVs/subj 0.4978 0.4639 4.62E-02 0.1603 0.1470 1.74E-01       
Subjs w CNV 0.3739 0.3502 2.10E-02 0.1381 0.1344 3.42E-01       
Genes/CNV 0.8711 0.7879 2.53E-02 0.2855 0.2401 6.11E-02       
Genes/CNV kb 0.0275 0.0272 4.05E-01 0.0315 0.0318 5.45E-01       
Exon-
containing 
CNVs/subj 0.3227 0.2925 3.24E-02 0.1190 0.1054 1.33E-01       
Subjs w CNV 0.2636 0.2426 2.55E-02 0.1039 0.0996 2.99E-01       
Genes/CNV 2.1170 1.7490 9.85E-03 0.7472 0.5530 2.59E-02       
Genes/CNV kb 0.0549 0.0523 2.40E-01 0.0620 0.0591 3.47E-01       
Intronic CNVs/subj 0.1751 0.1714 3.72E-01 0.0487 0.0484 5.04E-01       Subjs w CNV 0.1591 0.1535 2.76E-01 0.0466 0.0469 5.50E-01       
 


















Dup Type of CNV Tested effect 
All (< 1%) Singleton CNVs > 500 kb CNVs > 1 Mb CNVs 





All CNVs/subj 0.4790 0.5003 8.50E-01 0.1178 0.1264 8.29E-01 0.0678 0.0731 7.96E-01 0.0160 0.0179 7.48E-01 
Subjs w CNV 0.3607 0.3721 8.35E-01 0.1054 0.1134 8.60E-01 0.0638 0.0700 8.53E-01 0.0157 0.0176 7.54E-01 
Intergenic CNVs/subj 0.0823 0.0839 6.00E-01 0.0299 0.0277 3.31E-01 0.0071 0.0068 4.98E-01 0.0009 0.0006 5.02E-01 
Subjs w CNV 0.0768 0.0792 6.61E-01 0.0290 0.0268 3.24E-01 0.0071 0.0068 4.98E-01 0.0009 0.0006 5.02E-01 
Gene-
containing 
CNVs/subj 0.3967 0.4165 8.52E-01 0.0946 0.1067 9.23E-01 0.0607 0.0663 8.22E-01 0.0151 0.0173 7.82E-01 
Subjs w CNV 0.3132 0.3187 6.92E-01 0.0848 0.0983 9.74E-01 0.0583 0.0632 8.11E-01 0.0148 0.0170 7.89E-01 
Genes/CNV 2.5020 2.7340 8.34E-01 0.3995 0.5000 9.46E-01 0.8086 0.9695 8.65E-01 0.3708 0.4454 7.39E-01 
Genes/CNV kb 0.0179 0.0178 4.16E-01 0.0153 0.0176 9.50E-01 0.0127 0.0141 8.25E-01 0.0140 0.0139 4.94E-01 
Exon-
containing 
CNVs/subj 0.3930 0.4137 8.64E-01 0.0928 0.1057 9.41E-01 0.0607 0.0663 8.23E-01 0.0151 0.0173 7.80E-01 
Subjs w CNV 0.3110 0.3172 7.12E-01 0.0835 0.0977 9.79E-01 0.0583 0.0632 8.11E-01 0.0148 0.0170 7.86E-01 
Genes/CNV 15.2500 16.7100 8.14E-01 2.2780 2.9420 9.56E-01 5.6890 6.8400 8.67E-01 2.6820 3.2410 7.49E-01 
Genes/CNV kb 0.0989 0.0955 2.41E-01 0.0809 0.0979 9.80E-01 0.0902 0.0978 7.61E-01 0.1015 0.1025 5.21E-01 
Intronic CNVs/subj 0.0037 0.0028 3.29E-01 0.0022 0.0015 3.88E-01 0.0000 0.0000 1.00E+00 0.0000 0.0000 1.00E+00 
Subjs w CNV 0.0037 0.0028 3.29E-01 0.0022 0.0015 3.88E-01 0.0000 0.0000 1.00E+00 0.0000 0.0000 1.00E+00 
Short (< 
100 kb) 
All CNVs/subj 0.6510 0.6609 6.63E-01 0.2263 0.2420 8.69E-01       Subjs w CNV 0.4553 0.4448 1.99E-01 0.1924 0.1961 6.59E-01       
Intergenic CNVs/subj 0.2478 0.2408 3.00E-01 0.0925 0.0863 2.27E-01       Subjs w CNV 0.2118 0.2065 3.10E-01 0.0863 0.0798 1.84E-01       
Gene-
containing 
CNVs/subj 0.4032 0.4202 8.17E-01 0.1384 0.1618 9.82E-01       
Subjs w CNV 0.3200 0.3113 2.32E-01 0.1224 0.1335 9.16E-01       
Genes/CNV 0.9084 0.9701 8.63E-01 0.3110 0.3419 8.55E-01       
Genes/CNV kb 0.0328 0.0325 4.18E-01 0.0332 0.0342 6.56E-01       
Exon-
containing 
CNVs/subj 0.3332 0.3499 8.37E-01 0.1181 0.1359 9.64E-01       
Subjs w CNV 0.2731 0.2673 3.07E-01 0.1057 0.1147 8.82E-01       
Genes/CNV 3.5310 3.6040 6.07E-01 1.1200 1.1820 6.81E-01       
Genes/CNV kb 0.1120 0.1001 2.89E-02 0.1018 0.1026 5.27E-01       
Intronic CNVs/subj 0.0700 0.0703 5.36E-01 0.0219 0.0290 9.66E-01       Subjs w CNV 0.0681 0.0650 3.25E-01 0.0210 0.0284 9.77E-01       
Shown are results of global burden analysis on down-sampled dataset consisting of 6,488 subjects in which there were equal number of male 
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Table S10. Manually checked genes and regions with stratified permutation test and CMH test P < 0.01. 
 

































































































































MSR1 8 15,965,386 16,050,300 55 32 2.05E-03 1.96 1.93E-03 23 10 6 3 15 10 11 9 + Y Y Y Y 5.68E-02 Y 
FAILED QC 
NEU4 2 242,750,159 242,758,739 12 2 4.59E-03 6.53 4.89E-03 12 2 0 0 0 0 0 0 + Y Y Y N 1.38E-04 N 
LOC93622 4 6,675,820 6,677,774 25 3 7.00E-05 7.60 6.96E-05 0 0 25 3 0 0 0 0 - Y Y Y Y 8.65E-39 N 
PRKN 6 161,768,589 163,148,834 29 16 1.63E-02 2.03 1.72E-02 15 9 3 3 4 2 7 2 + Y Y Y Y 3.44E-01 N 
LOC441242 7 64,600,748 65,235,797 7 0 4.55E-03 Inf 4.34E-03 1 0 0 0 3 0 3 0 + Y Y Y N 1.60E-01 N 
PEMT 17 17,408,876 17,495,017 16 0 2.00E-05 Inf 1.20E-05 16 0 0 0 0 0 0 0 - Y Y Y Y 3.40E-05 N 
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 PASSED QC  
TUBGCP5 15 22,833,394 22,873,891 24 7 7.80E-04 3.88 7.58E-04 7 3 11 0 2 1 4 3 + Y Y Y Y 2.32E-03 Y 
CYFIP1 15 22,892,648 23,003,603 24 7 7.80E-04 3.88 7.58E-04 7 3 11 0 2 1 4 3 + Y Y Y Y 4.28E-03 Y 
NIPA2 15 23,004,683 23,034,427 24 7 8.60E-04 3.88 7.58E-04 7 3 11 0 2 1 4 3 + Y Y Y Y 4.28E-03 Y 
NIPA1 15 23,043,278 23,086,843 24 7 6.70E-04 3.88 7.58E-04 7 3 11 0 2 1 4 3 + Y Y Y Y 4.28E-03 Y 
FAILED QC 
NBPF1 1 16,888,921 16,940,100 54 40 9.07E-03 1.70 8.21E-03 0 0 5 1 11 15 38 24 + N Y Y N 1.26E-20 N 
CROCCP2 1 16,944,750 16,957,401 57 41 4.22E-03 1.77 4.17E-03 0 0 5 1 12 15 40 25 + N Y Y N 9.36E-22 N 
TM4SF20 2 228,226,873 228,244,022 91 63 2.73E-03 1.67 2.68E-03 1 0 90 63 0 0 0 0 + Low Y Low N 2.59E-213 N 
HLA-DQA1 6 32,605,182 32,611,429 25 10 7.30E-03 2.69 7.09E-03 0 1 25 9 0 0 0 0 - Low Y Low N 2.18E-45 N 
PRH1-PRR4 12 10,998,447 11,324,224 31 13 4.72E-03 2.53 4.36E-03 0 0 31 12 0 0 0 1 ? Low Y Y N 6.05E-58 N 
PRH1 12 11,033,559 11,324,222 31 13 4.21E-03 2.53 4.36E-03 0 0 31 12 0 0 0 1 ? Low Y Y N 6.05E-58 N 
TAS2R46 12 11,213,963 11,214,893 31 12 2.58E-03 2.74 2.59E-03 0 0 31 12 0 0 0 0 ? Low Y Y N 1.03E-59 N 
TAS2R43 12 11,243,885 11,244,912 31 12 2.69E-03 2.74 2.59E-03 0 0 31 12 0 0 0 0 ? Low Y Y N 1.03E-59 N 
RASA3 13 114,747,193 114,898,095 30 9 2.00E-04 3.81 1.65E-04 26 8 1 1 3 0 0 0 - Y Y Y Y 7.37E-08 N 
ZFYVE1 14 73,436,152 73,493,920 3 0 3.86E-02 Inf 3.98E-02 1 0 0 0 1 0 1 0 + Y Y Y Y 8.30E-01 N 
ASPG 14 104,552,022 104,579,046 24 3 8.00E-05 7.63 5.24E-05 23 3 0 0 0 0 1 0 + Y Y Low Y 1.38E-07 N 
MIR203A 14 104,583,741 104,583,851 24 3 8.00E-05 7.63 5.24E-05 23 3 0 0 0 0 1 0 + Y Y Low Y 1.38E-07 N 
MIR203B 14 104,583,754 104,583,840 24 3 5.00E-05 7.63 5.24E-05 23 3 0 0 0 0 1 0 + Y Y Low Y 1.38E-07 N 
KIF26A 14 104,605,059 104,647,235 23 3 1.20E-04 7.26 9.69E-05 23 3 0 0 0 0 0 0 + Y Y Low Y 2.84E-08 N 
GOLGA8DP 15 22,702,284 22,715,728 9 1 8.34E-03 10.36 8.25E-03 0 0 6 0 2 0 1 1 + Y Y Y Y 1.41E-04 N 
GOLGA6L1 15 22,736,245 22,746,002 9 1 8.80E-03 10.36 8.25E-03 0 0 6 0 2 0 1 1 + Y Y Y Y 1.41E-04 N 
GOLGA6L22 15 22,736,267 22,746,002 9 1 8.04E-03 10.36 8.25E-03 0 0 6 0 2 0 1 1 + Y Y Y Y 1.41E-04 N 
LOC283683 15 23,094,330 23,115,254 24 6 4.10E-04 4.49 3.56E-04 7 2 11 0 2 1 4 3 + Y Y Y Y 2.79E-03 N 
WHAMMP3 15 23,187,728 23,208,357 20 5 8.70E-04 4.59 9.93E-04 4 1 11 0 2 1 3 3 + Y Y Y Y 1.31E-04 N 
HERC2P2 15 23,282,264 23,378,259 13 3 4.80E-03 5.33 4.88E-03 0 0 9 0 2 1 2 2 + Y Y Y Y 3.13E-06 N 
ERVV-1 19 53,517,343 53,519,833 85 66 5.71E-03 1.59 5.92E-03 4 3 80 61 0 1 1 1 + Y Y Y N 5.40E-181 N 
LILRB3 19 54,720,146 54,746,711 77 47 4.70E-04 1.95 3.92E-04 20 7 48 33 6 3 3 4 + Y Y Y N 9.74E-63 N 
TPTE 21 10,906,186 10,990,943 60 29 1.00E-05 3.30 2.46E-07 0 0 3 4 57 25 0 0 - N Y Y N 5.94E-74 N 
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chr6:162,136,159-163,489,668 65 40 8.90E-04 1.92 9.74E-04 33 17 10 11 9 5 13 7 + Y Y Y Y 2.02E-01 Y 
chr6:162,177,023-163,489,668 65 40 9.50E-04 1.92 9.74E-04 33 17 10 11 9 5 13 7 + Y Y Y Y 2.02E-01 Y 
chr6:162,804,504-164,033,649 55 35 3.66E-03 1.84 3.63E-03 26 11 9 10 8 4 12 10 + Y Y Y Y 8.02E-01 Y 
chr8:15,817,196-16,045,585 58 33 9.50E-04 2.03 9.74E-04 24 10 17 11 6 3 11 9 + Y Y Y Y 1.15E-02 Y 
chr8:15,817,196-16,092,656 59 33 8.10E-04 2.05 7.45E-04 24 10 18 11 6 3 11 9 + Y Y Y Y 6.03E-03 Y 
FAILED QC 
chr1:106,307,942-106,367,506 23 2 1.00E-05  14.71  1.89E-06 0 0 0 0 20 0 3 2 - N Y Y Y 5.61E-21 N 
chr1:106,327,837-106,371,203 20 0 1.00E-05  Inf  1.66E-07 0 0 0 0 20 0 0 0 - N Y Y Y 1.13E-27 N 
chr2:57,270,600-57,595,408 7 0 2.82E-03  Inf  2.96E-03 2 0 1 0 2 0 2 0 + Y Y Y Y 6.86E-01 N 
chr2:89,141,311-90,403,624 13 1 4.70E-04  16.51  4.25E-04 0 0 0 0 13 1 0 0 ? N N Y N 2.28E-19 N 
chr4:36,894,737-36,936,789 21 5 7.10E-04  4.74  7.26E-04 0 0 10 1 9 3 2 1 + Y Y Y Y 3.03E-09 N 
chr4:6,618,624-6,652,800 25 5 4.70E-04  4.75  4.71E-04 0 0 0 0 25 4 0 1 - Y Y Y Y 1.93E-38 N 
chr4:6,627,084-6,687,545 25 5 6.00E-04  4.75  4.71E-04 0 0 0 0 25 4 0 1 - Y Y Y Y 1.93E-38 N 
chr4:186,394,634-186,421,724 14 4 5.91E-03  4.27  5.52E-03 0 0 2 2 0 0 12 2 + Low Y Y Y 1.03E-05 N 
chr8:14,802,942-14,825,833 5 0 4.15E-02 Inf 4.21E-02 1 0 2 0 1 0 1 0 + Y Y Y Y 5.34E-01 N 
chr15:94,779,085-94,829,625 15 6 1.27E-02 3.16 1.29E-02 10 2 1 3 2 1 2 0 + Y Y Y Y 2.61E-01 N 
chr17:17,400,972-17,444,638 16 0 2.00E-05  Inf  1.20E-05 16 0 0 0 0 0 0 0 - Y Y Y Y 3.40E-05 N 
chr20:14,569,942-15,082,546 84 (83) 66 6.22E-03  1.55  5.84E-03 30 19 13 13 18 13 23 21 + Y Y Y N 4.00E-02 N 
chr20:14,569,942-15,100,284 84 (83) 67 7.81E-03  1.52  7.80E-03 30 20 13 13 18 13 23 21 + Y Y Y N 4.88E-02 N 
chr20:14,569,942-15,170,143 84 (83) 67 8.28E-03  1.52  7.80E-03 30 20 13 13 18 13 23 21 + Y Y Y N 4.88E-02 N 
chr20:14,569,942-15,107,038 84 (83) 67 8.50E-03  1.52  7.80E-03 30 20 13 13 18 13 23 21 + Y Y Y N 4.88E-02 N 
chr20:14,714,457-15,234,769 80 (79) 62 6.57E-03  1.57  5.96E-03 30 20 12 12 15 13 23 17 + Y Y Y N 1.54E-01 N 
chr20:14,837,263-15,254,051 66 (65) 50 8.94E-03  1.62  8.25E-03 28 17 11 9 11 10 16 14 + Y Y Y N 5.37E-01 N 
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PASSED QC  
chr6:106,549,398-107,026,323 6 0 6.06E-03 Inf 5.93E-03 2 0 1 0 0 0 3 0 + Y Y Y Y 5.88E-01 Y 
chr15:22,652,330-23,309,294 24 7 7.80E-04 3.88 7.58E-04 7 3 2 1 11 0 4 3 + Y Y Y Y 2.32E-03 Y 
FAILED QC 
chr1:188,993,946-189,828,204 19 7 9.18E-03 2.98 9.33E-03 13 2 0 1 4 3 2 1 - Y Y Y Y 1.33E-02 N 
chr1:188,993,946-189,870,893 19 7 9.45E-03 2.98 9.33E-03 13 2 0 1 4 3 2 1 - Y Y Y Y 1.33E-02 N 
chr4:33,223,075-33,512,554 9 1 5.17E-03 11.08 5.14E-03 9 1 0 0 0 0 0 0 - Y Y Y Y 2.20E-03 N 
chr6:27,601,587-28,004,982 25 13 9.36E-03 2.38 9.48E-03 1 1 5 5 9 5 10 2 + Y Y Y Y 2.34E-06 N 
chr6:27,601,587-27,985,388 25 13 9.49E-03 2.38 9.48E-03 1 1 5 5 9 5 10 2 + Y Y Y Y 2.34E-06 N 
chr7:6,065,194-6,518,359 2 0 7.13E-02 Inf 7.10E-02 0 0 1 0 1 0 0 0 + Y Y Y Y 2.10E-01 N 
chr9:10,412,112-11,645,495 32 18 3.87E-03 2.34 3.78E-03 3 6 27 1 0 10 2 1 - Y Y Y Y 1.64E-12 N 
chr9:10,412,112-11,321,119 31 18 5.81E-03 2.24 6.05E-03 2 6 27 1 0 10 2 1 - Y Y Y Y 5.18E-13 N 
chr12:129,153,544-129,581,856 20 11 3.32E-02 2.12 3.48E-02 11 6 3 3 1 1 5 1 + Y Y Y Y 3.14E-01 N 
chr13:114,576,614-115,108,397 35 14 6.80E-04 2.84 5.93E-04 28 12 3 0 2 2 2 0 - Y Y Y Y 1.13E-07 N 
chr13:114,610,675-115,108,397 34 10 8.00E-05 3.86 5.58E-05 27 9 3 0 2 1 2 0 - Y Y Y Y 6.65E-07 N 
chr13:114,740,938-115,108,397 34 10 8.00E-05 3.86 5.58E-05 27 9 3 0 2 1 2 0 - Y Y Y Y 6.65E-07 N 
chr14:104,478,511-104,640,011 24 3 6.00E-05 7.63 5.24E-05 23 3 0 0 0 0 1 0 + Y Low Y Y 1.38E-07 N 
chr18:50,127,781-50,166,065 4 0 4.84E-02 Inf 4.95E-02 2 0 1 0 1 0 0 0 + Y Y Y Y 6.33E-01 N 
 
Shown are the numbers of CNVs in each gene or CNV region for all cohorts combined and also for each cohort with CMH p < 0.01 and 
permutation p < 0.01 for manual review, separately for deletions and duplications. Value in parentheses is the number of individuals carrying 
the CNV if it is not the same number as CNVs. All tests were stratified for batch and sex. Emp p-value = empirical (permutation-based) p-
values. CMH = Cochrane-Mantel-Haenszel exact tests. OR = odds ratio. Inf = infinite, OR not calculable with 0 CNVs in cases. Prop test p-
value = proportion test p-values. In column RADIANT cov, Affy cov, and GR Illum cov, Y = >10 probes on the genotyping platform, N = no 
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Table S11. Summary of number of CNV calls. 
 
Cohort CNV type Total CNVs CNVs/subject Long (>100 kb) Long CNVs/subject Short (<100 kb) Short CNVs/subject 
Combined 
cohorts 
ALL 217,339 17.5189 53,133 4.2828 164,206 13.2360 
Deletions 155,636 12.5452 24,611 1.9838 131,025 10.5614 
Duplications 61,703 4.9736 28,522 2.2990 33,181 2.6746 
RARE (<1%) 30,871 2.4884 10,005 0.8065 20,866 1.6819 
Deletions 16,326 1.3160 3,982 0.3210 12,344 0.9950 
Duplications 14,545 1.1724 6,023 0.4855 8,522 0.6869 
RADIANT 
cohort 
ALL 20,402 4.0424 8,239 1.6325 12,163 2.4099 
Deletions 11,095 2.1983 2,914 0.5774 8,181 1.6210 
Duplications 9,307 1.8441 5,325 1.0551 3,982 0.7890 
RARE (<1%) 8,293 1.6432 3,906 0.7739 4,387 0.8692 
Deletions 3,721 0.7373 1,455 0.2883 2,266 0.4490 
Duplications 4,572 0.9059 2,451 0.4856 2,121 0.4202 
NESDA/NTR 
cohort 
ALL 88,641 25.4642 21,772 6.2545 66,869 19.2097 
Deletions 65,938 18.9423 9,721 2.7926 56,217 16.1497 
Duplications 22,703 6.5220 12,051 3.4619 10,652 3.0600 
RARE (<1%) 10,190 2.9273 2,917 0.8380 7,273 2.0893 
Deletions 5,700 1.6375 1,158 0.3327 4,542 1.3048 
Duplications 4,490 1.2899 1,759 0.5053 2,731 0.7845 
GenRED 
cohort 
ALL 54,841 24.8712 14,214 6.4463 40,627 18.4249 
Deletions 42,077 19.0825 8,051 3.6512 34,026 15.4313 
Duplications 12,764 5.7887 6,163 2.7950 6,601 2.9937 
RARE (<1%) 6,074 2.7546 1,705 0.7732 4,369 1.9814 
Deletions 3,471 1.5741 771 0.3497 2,700 1.2245 
Duplications 2,603 1.1805 934 0.4236 1,669 0.7569 
GenRED-II 
cohort 
ALL 53,455 31.9516 8,908 5.3246 44,547 26.6270 
Deletions 36,526 21.8326 3,925 2.3461 32,601 19.4866 
Duplications 16,929 10.1189 4,983 2.9785 11,946 7.1405 
RARE (<1%) 6,314 3.7741 1,477 0.8828 4,837 2.8912 
Deletions 3,434 2.0526 598 0.3574 2,836 1.6952 
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RADIANT (<1%) GenRED II (<1%) GenRED (<1%) NESDA/NTR (<1%) 
OR 2.50% 97.50% p value OR 2.50% 97.50% p value OR 2.50% 97.50% p value OR 2.50% 97.50% p value 
Long 
(>100kb) 
All 1.0287 0.9270 1.1415 5.94E-01 1.1880 0.9973 1.4176 5.46E-02 1.0167 0.8726 1.1839 8.31E-01 0.9789 0.8712 1.0993 7.19E-01 
Genic 0.9699 0.8473 1.1096 6.57E-01 1.1486 0.9104 1.4510 2.44E-01 1.1131 0.9154 1.3530 2.82E-01 1.1370 0.9732 1.3282 1.05E-01 
Exonic 0.9371 0.8154 1.0761 3.58E-01 1.0951 0.8558 1.4027 4.71E-01 1.1561 0.9421 1.4182 1.64E-01 1.1660 0.9932 1.3691 6.05E-02 
Intronic 1.5676 0.9374 2.6645 9.00E-02 1.8301 0.8607 4.1014 1.26E-01 0.7676 0.3976 1.4456 4.19E-01 0.7474 0.3688 1.4535 4.00E-01 
Intergenic 1.1201 0.9522 1.3181 1.71E-01 1.2167 0.9451 1.5708 1.30E-01 0.8856 0.6938 1.1266 3.25E-01 0.8033 0.6700 0.9608 1.72E-02 
Short 
(<100kb) 
All 1.0490 0.9659 1.1394 2.56E-01 0.9958 0.9315 1.0646 9.03E-01 1.0871 1.0056 1.1754 3.57E-02 1.0692 1.0130 1.1316 1.83E-02 
Genic 1.1496 1.0281 1.2859 1.46E-02 0.9352 0.8489 1.0289 1.71E-01 1.0646 0.9517 1.1909 2.74E-01 1.0444 0.9716 1.1289 2.52E-01 
Exonic 1.2494 1.0913 1.4317 1.30E-03 0.9253 0.8209 1.0408 1.99E-01 1.1099 0.9632 1.2794 1.50E-01 1.0402 0.9524 1.1442 3.91E-01 
Intronic 0.9606 0.7893 1.1685 6.88E-01 0.9461 0.7912 1.1308 5.42E-01 0.9934 0.8280 1.1904 9.43E-01 1.0655 0.9266 1.2248 3.73E-01 







RADIANT (<1%) GenRED II (<1%) GenRED (<1%) NESDA/NTR (<1%) 
OR 2.50% 97.50% p value OR 2.50% 97.50% p value OR 2.50% 97.50% p value OR 2.50% 97.50% p value 
Long 
(>100kb) 
All 0.9371 0.8710 1.0079 8.12E-02 1.1422 1.0025 1.3028 4.65E-02 1.0229 0.8920 1.1721 7.45E-01 1.0790 1.0089 1.1602 3.22E-02 
Genic 0.8981 0.8267 0.9748 1.05E-02 1.1286 0.9731 1.3101 1.10E-01 1.0764 0.9284 1.2473 3.28E-01 1.0782 1.0054 1.1631 4.19E-02 
Exonic 0.8964 0.8248 0.9733 9.54E-03 1.1139 0.9598 1.2937 1.56E-01 1.0810 0.9318 1.2534 3.03E-01 1.0757 1.0031 1.1603 4.81E-02 
Intronic 1.1570 0.4079 3.3611 7.82E-01 8.2454 1.2159 163.4242 6.17E-02 0.4937 0.0243 3.5696 5.40E-01 2.0466 0.6157 7.8386 2.55E-01 
Intergenic 1.1327 0.9452 1.3585 1.77E-01 1.2350 0.9138 1.6742 1.71E-01 0.7823 0.5530 1.0966 1.59E-01 1.1096 0.8598 1.4309 4.23E-01 
Short 
(<100kb) 
All 1.0024 0.9264 1.0843 9.53E-01 0.9128 0.8439 0.9837 1.93E-02 1.0876 0.9835 1.2025 1.01E-01 0.9919 0.9412 1.0437 7.54E-01 
Genic 0.9793 0.8916 1.0749 6.60E-01 0.9915 0.8955 1.0967 8.69E-01 1.0420 0.9136 1.1879 5.39E-01 0.9745 0.9086 1.0420 4.56E-01 
Exonic 0.9503 0.8580 1.0513 3.25E-01 0.9707 0.8682 1.0833 5.97E-01 0.9800 0.8431 1.1381 7.92E-01 0.9931 0.9198 1.0704 8.57E-01 
Intronic 1.2247 0.9256 1.6247 1.57E-01 1.1558 0.8571 1.5628 3.44E-01 1.3057 0.9821 1.7377 6.65E-02 0.8053 0.6419 1.0042 5.74E-02 
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Table S13. Logistic regression analyses of global burden of CNVs. 
 
A. Deletions 
Type of Del Type of CNV Tested effect 
All (< 1%) Singleton CNVs > 500 kb CNVs > 1 Mb CNVs 
OR 2.50% 97.50% p value OR 2.50% 97.50% p value OR 2.50% 97.50% p value OR 2.50% 97.50% p value 




NSEG 1.0296 0.9658 1.0975 3.71E-01 1.1068 0.9466 1.2940 2.03E-01 1.1369 0.8832 1.4637 3.19E-01 1.4435 0.8839 2.3822 1.45E-01 
KB 1.0001 0.9999 1.0003 3.08E-01 1.0001 0.9996 1.0007 6.72E-01 1.0002 0.9999 1.0005 2.08E-01 1.0002 0.9999 1.0006 2.34E-01 
Gene-
containing 
NSEG 1.0606 0.9754 1.1531 1.68E-01 1.0987 0.9169 1.3164 3.07E-01 1.1239 0.8586 1.4707 3.94E-01 1.3108 0.7780 2.2253 3.10E-01 
KB 1.0001 0.9999 1.0004 2.35E-01 1.0002 0.9996 1.0007 5.29E-01 1.0001 0.9999 1.0004 3.20E-01 1.0002 0.9998 1.0005 3.98E-01 
Exon-
containing 
NSEG 1.0521 0.9646 1.1475 2.51E-01 1.1105 0.9242 1.3343 2.63E-01 1.1239 0.8586 1.4707 3.94E-01 1.3108 0.7780 2.2253 3.10E-01 
KB 1.0001 0.9999 1.0004 2.69E-01 1.0002 0.9997 1.0008 4.16E-01 1.0001 0.9999 1.0004 3.20E-01 1.0002 0.9998 1.0005 3.98E-01 
Intronic NSEG 1.1672 0.8591 1.5876 3.23E-01 1.2429 0.6541 2.3868 5.07E-01 NA NA NA NA NA NA NA NA 
KB 1.0008 0.9988 1.0028 4.49E-01 1.0002 0.9956 1.0048 9.32E-01 NA NA NA NA NA NA NA NA 
Intergenic NSEG 0.9881 0.8956 1.0899 8.11E-01 1.1758 0.9066 1.5248 2.22E-01 1.2482 0.5924 2.6818 5.61E-01 3.1975 0.7163 22.2489 1.62E-01 
KB 1.0000 0.9995 1.0004 9.20E-01 1.0005 0.9992 1.0019 4.67E-01 1.0005 0.9996 1.0015 3.04E-01 1.0009 0.9996 1.0025 1.98E-01 
Short (< 
100 kb) 
All NSEG 1.0483 1.0139 1.0843 5.92E-03 1.0664 0.9955 1.1473 7.70E-02 
  
KB 1.0011 1.0004 1.0019 3.93E-03 1.0020 1.0003 1.0037 2.32E-02 
Gene-
containing 
NSEG 1.0343 0.9877 1.0842 1.56E-01 1.0224 0.9377 1.1191 6.17E-01 
KB 1.0010 1.0000 1.0021 4.74E-02 1.0012 0.9993 1.0033 2.41E-01 
Exon-
containing 
NSEG 1.0552 0.9965 1.1192 6.95E-02 1.0360 0.9382 1.1510 4.90E-01 
KB 1.0013 1.0002 1.0025 2.61E-02 1.0013 0.9992 1.0035 2.52E-01 
Intronic NSEG 0.9952 0.9149 1.0825 9.11E-01 0.9425 0.7822 1.1342 5.31E-01 
KB 1.0001 0.9979 1.0022 9.39E-01 0.9998 0.9948 1.0049 9.46E-01 
Intergenic NSEG 1.0716 1.0190 1.1270 7.14E-03 1.1574 1.0338 1.2962 1.13E-02 
KB 1.0014 1.0002 1.0026 2.26E-02 1.0032 1.0006 1.0059 1.74E-02 
 

























Dup Type of CNV 
Tested 
effect 
All (< 1%) Singleton CNVs > 500 kb CNVs > 1 Mb CNVs 
OR 2.50% 97.50% p value OR 2.50% 97.50% p value OR 2.50% 97.50% p value OR 2.50% 97.50% p value 
Long (> 
100 kb or 
longer) 
All NSEG 1.0268 0.9837 1.0725 2.29E-01 1.1097 0.9876 1.2484 8.13E-02 0.9819 0.8599 1.1207 7.87E-01 0.9906 0.7461 1.3136 9.48E-01 
KB 1.0000 0.9999 1.0001 5.29E-01 1.0002 0.9998 1.0006 3.26E-01 1.0000 0.9999 1.0001 9.32E-01 1.0000 0.9999 1.0002 7.75E-01 
Gene-
containing 
NSEG 1.0187 0.9723 1.0677 4.37E-01 1.0483 0.9236 1.1908 4.66E-01 0.9708 0.8438 1.1165 6.79E-01 0.9466 0.7075 1.2643 7.11E-01 
KB 1.0000 0.9999 1.0001 8.93E-01 1.0000 0.9996 1.0004 9.63E-01 1.0000 0.9998 1.0001 7.10E-01 1.0000 0.9998 1.0001 7.54E-01 
Exon-
containing 
NSEG 1.0166 0.9702 1.0657 4.89E-01 1.0426 0.9179 1.1850 5.21E-01 0.9708 0.8438 1.1165 6.79E-01 0.9466 0.7075 1.2643 7.11E-01 
KB 1.0000 0.9999 1.0001 9.10E-01 1.0000 0.9996 1.0003 8.54E-01 1.0000 0.9998 1.0001 7.10E-01 1.0000 0.9998 1.0001 7.54E-01 
Intronic NSEG 1.5254 0.7880 3.0095 2.13E-01 1.3693 0.5310 3.6480 5.16E-01 NA NA NA NA NA NA NA NA 
KB 1.0007 0.9981 1.0033 6.11E-01 1.0026 0.9956 1.0100 4.79E-01 NA NA NA NA NA NA NA NA 
Intergenic NSEG 1.0912 0.9654 1.2333 1.62E-01 1.1908 0.9304 1.5262 1.66E-01 1.0894 0.7098 1.6726 6.94E-01 2.4597 0.6690 11.6064 1.99E-01 




NSEG 0.9850 0.9512 1.0194 3.90E-01 0.9925 0.9219 1.0681 8.41E-01 
   
KB 0.9997 0.9990 1.0004 4.69E-01 1.0000 0.9986 1.0015 9.45E-01 
Gene-
containing 
NSEG 0.9845 0.9410 1.0296 4.96E-01 0.9607 0.8716 1.0581 4.17E-01 
KB 0.9999 0.9990 1.0007 7.73E-01 0.9998 0.9981 1.0015 8.15E-01 
Exon-
containing 
NSEG 0.9730 0.9253 1.0225 2.83E-01 0.9392 0.8452 1.0426 2.41E-01 
KB 0.9997 0.9989 1.0006 5.72E-01 0.9995 0.9977 1.0013 5.78E-01 
Intronic NSEG 1.0586 0.9285 1.2066 3.94E-01 0.9088 0.7050 1.1681 4.57E-01 
KB 1.0017 0.9983 1.0051 3.18E-01 0.9983 0.9924 1.0042 5.75E-01 
Intergenic NSEG 0.9788 0.9166 1.0449 5.21E-01 1.0510 0.9282 1.1911 4.33E-01 
KB 0.9993 0.9978 1.0007 3.17E-01 1.0009 0.9983 1.0035 4.87E-01 
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RADIANT All (<1%) GR Illum All (<1%) GR Affy All (<1%) Neth All (<1%) Cochran’s 
Q-test  
p-value 
Fixed effect model 
Beta SE Beta SE Beta SE Beta SE Beta 2.50% 97.50% p-value 
Long 
(>100kb) 
All 0.0283 0.0531 0.1723 0.0896 0.0166 0.0778 -0.0213 0.0593 0.3475 0.0303 -0.0340 0.0947 0.3551 
Genic -0.0306 0.0688 0.1385 0.1188 0.1071 0.0996 0.1284 0.0793 0.3719 0.0638 -0.0204 0.1480 0.1376 
Exonic -0.0650 0.0707 0.0909 0.1259 0.1450 0.1043 0.1536 0.0818 0.1607 0.0575 -0.0297 0.1448 0.1964 
Intronic 0.4495 0.2652 0.6044 0.3945 -0.2645 0.3271 -0.2912 0.3458 0.1201 0.1399 -0.1765 0.4564 0.3861 
Intergenic 0.1134 0.0829 0.1961 0.1294 -0.1215 0.1235 -0.2190 0.0919 0.0133 -0.0146 -0.1140 0.0847 0.7732 
Short 
(<100kb) 
All 0.0479 0.0421 -0.0042 0.0340 0.0835 0.0398 0.0669 0.0284 0.3086 0.0482 0.0141 0.0823 0.0056 
Genic 0.1394 0.0571 -0.0670 0.0489 0.0626 0.0572 0.0434 0.0379 0.0467 0.0371 -0.0101 0.0843 0.1230 
Exonic 0.2226 0.0692 -0.0777 0.0604 0.1043 0.0724 0.0394 0.0459 0.0103 0.0555 -0.0023 0.1134 0.0598 
Intronic -0.0402 0.1000 -0.0554 0.0910 -0.0066 0.0925 0.0634 0.0711 0.7219 0.0020 -0.0827 0.0867 0.9635 







RADIANT All (<1%) GR Illum All (<1%) GR Affy All (<1%) Neth All (<1%) Cochran’s 
Q-test  
p-value 
Fixed effect model 
Beta SE Beta SE Beta SE Beta SE Beta 2.50% 97.50% p-value 
Long 
(>100kb) 
All -0.0649 0.0372 0.1329 0.0668 0.0227 0.0696 0.0760 0.0355 0.0147 0.0246 -0.0198 0.0690 0.2779 
Genic -0.1075 0.0420 0.1210 0.0758 0.0736 0.0753 0.0753 0.0370 0.0033 0.0171 -0.0312 0.0653 0.4887 
Exonic -0.1094 0.0422 0.1079 0.0761 0.0779 0.0756 0.0730 0.0369 0.0040 0.0149 -0.0335 0.0632 0.5466 
Intronic 0.1458 0.5274 2.1097 1.1290 -0.7059 1.1516 0.7162 0.6287 0.2981 0.4513 -0.2566 1.1593 0.2115 
Intergenic 0.1246 0.0924 0.2111 0.1541 -0.2456 0.1743 0.1040 0.1298 0.2148 0.0858 -0.0378 0.2094 0.1737 
Short 
(<100kb) 
All 0.0024 0.0401 -0.0913 0.0390 0.0839 0.0512 -0.0082 0.0261 0.0505 -0.0123 -0.0474 0.0227 0.4905 
Genic -0.0209 0.0476 -0.0085 0.0516 0.0411 0.0669 -0.0258 0.0346 0.8433 -0.0132 -0.0585 0.0320 0.5671 
Exonic -0.0510 0.0517 -0.0298 0.0564 -0.0202 0.0765 -0.0069 0.0383 0.9222 -0.0238 -0.0737 0.0262 0.3511 
Intronic 0.2027 0.1433 0.1448 0.1529 0.2667 0.1454 -0.2165 0.1139 0.0266 0.0556 -0.0778 0.1890 0.4144 
Intergenic 0.0633 0.0768 -0.2770 0.0714 0.1485 0.0807 0.0300 0.0551 0.0002 -0.0129 -0.0801 0.0544 0.7078 
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OR 95% CI Effect size p value 
Cases Control 
10-20 kb 0.3379 0.3298 1.0447 0.9840-1.1093 0.0438 1.52E-01 
20-30 kb 0.1708 0.1702 1.0313 0.9468-1.1233 0.0308 4.80E-01 
30-40 kb 0.1265 0.1186 1.0886 0.9825-1.2062 0.0849 1.05E-01 
40-50 kb 0.0998 0.1031 0.9843 0.8793-1.1016 -0.0158 7.84E-01 
50-60 kb 0.0644 0.0663 0.9675 0.8442-1.1077 -0.0331 6.32E-01 
60-70 kb 0.0673 0.0552 1.2465 1.0794-1.4403 0.2204 2.73E-03 
70-80 kb 0.0581 0.0521 1.1204 0.9630-1.3041 0.1137 1.41E-01 
80-90 kb 0.0505 0.0391 1.2945 1.0933-1.5340 0.2581 2.80E-03 




Table S16. Logistic regression analyses of global burden of all rare deletions and duplications. 
 
Type of CNV Type of CNV 
Combined cohort 
OR 2.50% 97.50% p value 
All rare deletion 
All 1.0435 1.0134 1.0748 4.56E-03 
Gene-containing 1.0402 0.9990 1.0837 5.77E-02 
Exon-containing 1.0537 1.0048 1.1060 3.25E-02 
Intronic 1.0064 0.9280 1.0913 8.77E-01 
Intergenic 1.0530 1.0071 1.1010 2.30E-02 
All rare duplication 
All 1.0010 0.9764 1.0261 9.39E-01 
Gene-containing 1.0007 0.9715 1.0306 9.65E-01 
Exon-containing 0.9966 0.9661 1.0279 8.31E-01 
Intronic 1.0730 0.9438 1.2195 2.81E-01 
Intergenic 1.0026 0.9473 1.0610 9.28E-01 
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Del Type of CNV Tested effect 
All (<1%) Singleton CNVs > 500 kb CNVs > 1 Mb CNVs 
Cases Controls p value Cases Controls p value Cases Controls p value Cases Controls p value 
Long (> 
100 kb or 
longer) 
All CNVs/subj 0.3336 0.3266 1.76E-01 0.0559 0.0501 8.11E-02 0.0216 0.0189 2.06E-01 0.0066 0.0044 9.50E-02 
Subjs w CNV 0.2879 0.2774 5.66E-02 0.0547 0.0485 6.50E-02 0.0215 0.0186 1.91E-01 0.0066 0.0044 9.50E-02 
Intergenic CNVs/subj 0.1370 0.1402 6.12E-01 0.0206 0.0180 1.07E-01 0.0028 0.0020 3.94E-01 0.0010 0.0003 1.18E-01 
Subjs w CNV 0.1275 0.1319 6.98E-01 0.0204 0.0178 1.14E-01 0.0028 0.0020 3.94E-01 0.0010 0.0003 1.18E-01 
Gene-
containing 
CNVs/subj 0.1965 0.1864 7.46E-02 0.0420 0.0377 1.49E-01 0.0189 0.0169 2.37E-01 0.0055 0.0041 2.03E-01 
Subjs w CNV 0.1820 0.1678 1.34E-02 0.0412 0.0371 1.66E-01 0.0189 0.0166 1.99E-01 0.0055 0.0041 2.03E-01 
Genes/CNV 0.7367 0.7247 3.74E-01 0.1285 0.1422 8.00E-01 0.2097 0.1656 1.09E-01 0.0931 0.0457 4.63E-02 
Genes/CNV kb 0.0099 0.0099 5.57E-01 0.0120 0.0132 8.91E-01 0.0113 0.0116 3.73E-01 0.0100 0.0079 1.66E-01 
Exon-
containing 
CNVs/subj 0.1815 0.1742 1.07E-01 0.0410 0.0365 1.24E-01 0.0189 0.0169 2.39E-01 0.0055 0.0041 2.00E-01 
Subjs w CNV 0.1682 0.1582 3.60E-02 0.0403 0.0359 1.29E-01 0.0189 0.0166 2.01E-01 0.0055 0.0041 2.00E-01 
Genes/CNV 3.9980 3.8080 2.69E-01 0.6933 0.7514 7.29E-01 1.3940 1.0450 6.51E-02 0.6121 0.3052 5.52E-02 
Genes/CNV kb 0.0484 0.0479 5.01E-01 0.0588 0.0676 9.20E-01 0.0742 0.0727 2.55E-01 0.0639 0.0525 2.03E-01 
Intronic CNVs/subj 0.0151 0.0122 2.07E-01 0.0036 0.0027 3.54E-01 0.0000 0.0000 1.00E+00 0.0000 0.0000 1.00E+00 
Subjs w CNV 0.0151 0.0119 1.70E-01 0.0036 0.0027 3.54E-01 0.0000 0.0000 1.00E+00 0.0000 0.0000 1.00E+00 
Short (< 
100 kb) 
All CNVs/subj 1.0760 1.0200 2.10E-04 0.2154 0.2021 4.90E-02       
Subjs w CNV 0.6040 0.5909 2.54E-03 0.1869 0.1730 8.46E-03       
Intergenic CNVs/subj 0.5564 0.5155 1.60E-04 0.1047 0.0928 1.10E-02       
Subjs w CNV 0.3986 0.3838 5.40E-03 0.0972 0.0872 1.43E-02       
Gene-
containing 
CNVs/subj 0.5197 0.5045 4.96E-02 0.1178 0.1162 3.34E-01       
Subjs w CNV 0.3844 0.3741 2.30E-02 0.1061 0.1055 3.47E-01       
Genes/CNV 0.9059 0.8676 4.28E-02 0.2087 0.1960 2.16E-01       
Genes/CNV kb 0.0264 0.0277 8.22E-01 0.0323 0.0344 7.69E-01       
Exon-
containing 
CNVs/subj 0.3349 0.3151 2.97E-02 0.0895 0.0859 2.85E-01       
Subjs w CNV 0.2727 0.2563 6.81E-03 0.0810 0.0788 3.40E-01       
Genes/CNV 2.1480 1.9660 5.34E-02 0.5413 0.5088 3.75E-01       
Genes/CNV kb 0.0523 0.0513 4.51E-01 0.0667 0.0683 7.92E-01       
Intronic CNVs/subj 0.1848 0.1894 4.17E-01 0.0351 0.0388 7.27E-01       
Subjs w CNV 0.1666 0.1677 2.54E-01 0.0337 0.0377 7.47E-01       
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B. Duplications 
Type of Dup Type of CNV Tested effect All (< 1%) Singleton CNVs > 500 kb CNVs > 1 Mb CNVs Cases Controls p value Cases Controls p value Cases Controls p value Cases Controls p value 
Long (> 100 kb or longer) 
All CNVs/subj 0.5298 0.5072 8.29E-02 0.0862 0.0746 2.52E-02 0.0735 0.0727 6.10E-01 0.0173 0.0166 5.14E-01 Subjs w CNV 0.3879 0.3824 3.55E-01 0.0777 0.0693 4.70E-02 0.0694 0.0697 6.92E-01 0.0170 0.0163 5.14E-01 
Intergenic CNVs/subj 0.0886 0.0818 1.18E-01 0.0225 0.0186 7.92E-02 0.0076 0.0066 4.12E-01 0.0012 0.0005 1.73E-01 Subjs w CNV 0.0837 0.0771 1.19E-01 0.0218 0.0181 8.31E-02 0.0076 0.0066 4.12E-01 0.0012 0.0005 1.73E-01 
Gene-containing 
CNVs/subj 0.4412 0.4254 1.46E-01 0.0702 0.0644 1.79E-01 0.0659 0.0661 6.59E-01 0.0161 0.0162 6.28E-01 
Subjs w CNV 0.3362 0.3319 3.65E-01 0.0633 0.0608 3.63E-01 0.0630 0.0635 6.79E-01 0.0157 0.0159 6.30E-01 
Genes/CNV 2.6420 2.6400 4.79E-01 0.2903 0.2703 3.95E-01 0.8031 0.8648 7.51E-01 0.3465 0.3842 7.08E-01 
Genes/CNV kb 0.0171 0.0181 9.68E-01 0.0162 0.0172 8.43E-01 0.0122 0.0130 6.54E-01 0.0126 0.0133 5.62E-01 
Exon-containing 
CNVs/subj 0.4375 0.4230 1.69E-01 0.0694 0.0641 2.06E-01 0.0659 0.0661 6.59E-01 0.0161 0.0162 6.26E-01 
Subjs w CNV 0.3336 0.3308 4.40E-01 0.0628 0.0605 3.76E-01 0.0630 0.0635 6.80E-01 0.0157 0.0159 6.27E-01 
Genes/CNV 15.9500 15.6200 3.68E-01 1.6970 1.6030 4.82E-01 5.5020 5.9640 7.53E-01 2.4240 2.7310 7.18E-01 
Genes/CNV kb 0.0933 0.0946 6.86E-01 0.0894 0.0960 8.84E-01 0.0837 0.0877 5.63E-01 0.0879 0.0953 5.98E-01 
Intronic CNVs/subj 0.0036 0.0024 1.03E-01 0.0017 0.0012 2.88E-01 0.0000 0.0000 1.00E+00 0.0000 0.0000 1.00E+00 Subjs w CNV 0.0036 0.0024 1.03E-01 0.0017 0.0012 2.88E-01 0.0000 0.0000 1.00E+00 0.0000 0.0000 1.00E+00 
Short (< 100 kb) 
All CNVs/subj 0.7299 0.7588 7.09E-01 0.1709 0.1778 6.68E-01       
Subjs w CNV 0.4917 0.4881 1.21E-01 0.1514 0.1476 1.49E-01       
Intergenic CNVs/subj 0.2855 0.2932 4.78E-01 0.0706 0.0699 2.52E-01       
Subjs w CNV 0.2412 0.2410 1.85E-01 0.0677 0.0631 5.87E-02       
Gene-containing 
CNVs/subj 0.4445 0.4656 7.81E-01 0.1064 0.1136 8.55E-01       
Subjs w CNV 0.3407 0.3390 2.49E-01 0.0962 0.0981 5.94E-01       
Genes/CNV 0.9993 1.0670 8.87E-01 0.2272 0.2377 7.12E-01       
Genes/CNV kb 0.0328 0.0327 6.16E-01 0.0325 0.0337 7.44E-01       
Exon-containing 
CNVs/subj 0.3664 0.3873 8.40E-01 0.0895 0.0977 9.12E-01       
Subjs w CNV 0.2901 0.2911 4.12E-01 0.0813 0.0848 7.56E-01       
Genes/CNV 3.7000 3.8390 7.45E-01 0.7990 0.8521 7.72E-01       
Genes/CNV kb 0.1045 0.0996 2.71E-01 0.0939 0.1026 9.06E-01       
Intronic CNVs/subj 0.0780 0.0783 3.76E-01 0.0190 0.0220 8.33E-01       
Subjs w CNV 0.0746 0.0731 2.28E-01 0.0189 0.0217 8.30E-01       
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Table S18. Global burden analyses of CNVs called by both QuantiSNP and PennCNV for Illumina data  
and by Birdsuite for Affymetrix data. 
 
A. Deletions 
Type of Del Type of CNV Tested effect All (<1%) Singleton CNVs > 500 kb CNVs > 1 Mb CNVs Cases Controls p value Cases Controls p value Cases Controls p value Cases Controls p value 
Long (> 100 kb or longer) 
All 
CNVs/subj 0.3163 0.3100 1.51E-01 0.0547 0.0486 6.35E-02 0.0215 0.0187 2.08E-01 0.0064 0.0044 1.11E-01 
Subjs w CNV 0.2756 0.2658 5.25E-02 0.0535 0.0469 4.93E-02 0.0213 0.0184 1.92E-01 0.0064 0.0044 1.11E-01 
Intergenic CNVs/subj 0.1301 0.1357 7.08E-01 0.0202 0.0178 1.11E-01 0.0026 0.0020 4.50E-01 0.0009 0.0003 1.72E-01 
Subjs w CNV 0.1215 0.1283 7.98E-01 0.0201 0.0177 1.18E-01 0.0026 0.0020 4.50E-01 0.0009 0.0003 1.72E-01 
Gene-containing 
CNVs/subj 0.1862 0.1743 3.66E-02 0.0412 0.0362 1.05E-01 0.0189 0.0168 2.24E-01 0.0055 0.0041 2.00E-01 
Subjs w CNV 0.1732 0.1586 8.14E-03 0.0403 0.0356 1.16E-01 0.0189 0.0165 1.87E-01 0.0055 0.0041 2.00E-01 
Genes/CNV 0.6995 0.6357 6.71E-02 0.1270 0.1361 7.23E-01 0.2097 0.1567 7.26E-02 0.0931 0.0457 4.66E-02 
Genes/CNV kb 0.0098 0.0093 1.78E-01 0.0120 0.0127 8.14E-01 0.0114 0.0110 2.68E-01 0.0103 0.0079 1.46E-01 
Exon-containing 
CNVs/subj 0.1711 0.1621 5.35E-02 0.0401 0.0350 8.32E-02 0.0189 0.0168 2.23E-01 0.0055 0.0041 2.00E-01 
Subjs w CNV 0.1593 0.1488 2.30E-02 0.0395 0.0344 8.59E-02 0.0189 0.0165 1.87E-01 0.0055 0.0041 2.00E-01 
Genes/CNV 3.7430 3.2060 3.38E-02 0.6834 0.7126 6.38E-01 1.3940 0.9834 4.00E-02 0.6121 0.3052 5.57E-02 
Genes/CNV kb 0.0465 0.0427 1.18E-01 0.0581 0.0637 8.39E-01 0.0748 0.0685 1.68E-01 0.0657 0.0525 1.83E-01 
Intronic CNVs/subj 0.0151 0.0122 2.07E-01 0.0036 0.0027 3.56E-01 0.0000 0.0000 1.00E+00 0.0000 0.0000 1.00E+00 
Subjs w CNV 0.0151 0.0119 1.71E-01 0.0036 0.0027 3.56E-01 0.0000 0.0000 1.00E+00 0.0000 0.0000 1.00E+00 
Short (< 100 kb) 
All CNVs/subj 0.9524 0.9042 6.00E-05 0.2099 0.1890 2.51E-03       
Subjs w CNV 0.5645 0.5572 5.98E-03 0.1811 0.1637 7.00E-04       
Intergenic CNVs/subj 0.4789 0.4491 2.60E-04 0.1022 0.0884 2.22E-03       
Subjs w CNV 0.3578 0.3471 6.17E-03 0.0952 0.0835 3.16E-03       
Gene-containing 
CNVs/subj 0.4735 0.4550 1.09E-02 0.1145 0.1067 6.58E-02       
Subjs w CNV 0.3621 0.3518 9.79E-03 0.1031 0.0987 8.18E-02       
Genes/CNV 0.8320 0.7822 7.28E-03 0.2066 0.1778 2.16E-02       
Genes/CNV kb 0.0276 0.0279 4.82E-01 0.0326 0.0334 4.62E-01       
Exon-containing 
CNVs/subj 0.3042 0.2818 5.26E-03 0.0869 0.0768 3.41E-02       
Subjs w CNV 0.2542 0.2386 4.65E-03 0.0787 0.0720 5.05E-02       
Genes/CNV 1.9670 1.7550 1.21E-02 0.5441 0.4555 8.59E-02       
Genes/CNV kb 0.0542 0.0515 2.38E-01 0.0661 0.0635 5.05E-01       
Intronic CNVs/subj 0.1694 0.1733 3.46E-01 0.0337 0.0367 6.02E-01       
Subjs w CNV 0.1547 0.1559 2.16E-01 0.0324 0.0358 6.41E-01       
 


















Dup Type of CNV Tested effect 
All (< 1%) Singleton CNVs > 500 kb CNVs > 1 Mb CNVs 
Cases Controls p value Cases Controls p value Cases Controls p value Cases Controls p value 
Long (> 
100 kb or 
longer) 
All CNVs/subj 0.4282 0.4147 1.19E-01 0.0766 0.0702 1.36E-01 0.0671 0.0644 4.11E-01 0.0145 0.0142 5.86E-01 Subjs w CNV 0.3334 0.3293 3.17E-01 0.0699 0.0667 3.08E-01 0.0638 0.0628 5.48E-01 0.0144 0.0142 6.11E-01 
Intergenic CNVs/subj 0.0671 0.0697 6.82E-01 0.0182 0.0168 3.54E-01 0.0061 0.0060 6.21E-01 0.0005 0.0003 4.81E-01 Subjs w CNV 0.0652 0.0670 6.54E-01 0.0182 0.0163 2.71E-01 0.0061 0.0060 6.21E-01 0.0005 0.0003 4.81E-01 
Gene-
containing 
CNVs/subj 0.3611 0.3450 7.56E-02 0.0649 0.0599 1.96E-01 0.0611 0.0584 3.84E-01 0.0140 0.0139 6.17E-01 
Subjs w CNV 0.2891 0.2819 1.76E-01 0.0587 0.0575 4.84E-01 0.0588 0.0571 4.53E-01 0.0138 0.0139 6.42E-01 
Genes/CNV 2.1920 2.0200 9.28E-02 0.2645 0.2483 3.81E-01 0.7280 0.6980 3.51E-01 0.3062 0.3346 6.66E-01 
Genes/CNV kb 0.0173 0.0168 2.71E-01 0.0161 0.0161 5.42E-01 0.0121 0.0114 1.57E-01 0.0133 0.0133 3.76E-01 
Exon-
containing 
CNVs/subj 0.3576 0.3426 8.82E-02 0.0640 0.0596 2.25E-01 0.0611 0.0584 3.85E-01 0.0140 0.0139 6.18E-01 
Subjs w CNV 0.2867 0.2809 2.26E-01 0.0581 0.0572 4.96E-01 0.0588 0.0571 4.55E-01 0.0138 0.0139 6.44E-01 
Genes/CNV 13.3900 12.0900 6.38E-02 1.5240 1.4700 4.61E-01 5.0550 4.8670 3.38E-01 2.1960 2.4320 6.63E-01 
Genes/CNV kb 0.0936 0.0871 1.98E-02 0.0859 0.0884 6.97E-01 0.0843 0.0777 7.59E-02 0.0953 0.0976 4.07E-01 
Intronic CNVs/subj 0.0035 0.0024 1.25E-01 0.0016 0.0012 3.58E-01 0.0000 0.0000 1.00E+00 0.0000 0.0000 1.00E+00 Subjs w CNV 0.0035 0.0024 1.25E-01 0.0016 0.0012 3.58E-01 0.0000 0.0000 1.00E+00 0.0000 0.0000 1.00E+00 
Short (< 
100 kb) 
All CNVs/subj 0.5389 0.5542 3.91E-01 0.1464 0.1542 6.19E-01       
Subjs w CNV 0.3952 0.3957 1.47E-01 0.1318 0.1310 1.61E-01       
Intergenic CNVs/subj 0.2093 0.2129 2.75E-01 0.0614 0.0623 3.40E-01       
Subjs w CNV 0.1849 0.1832 1.04E-01 0.0597 0.0571 9.88E-02       
Gene-
containing 
CNVs/subj 0.3296 0.3412 5.24E-01 0.0903 0.0966 7.39E-01       
Subjs w CNV 0.2675 0.2695 2.93E-01 0.0824 0.0854 5.59E-01       
Genes/CNV 0.7211 0.7701 8.13E-01 0.1919 0.2006 6.05E-01       
Genes/CNV kb 0.0316 0.0334 9.57E-01 0.0304 0.0331 8.92E-01       
Exon-
containing 
CNVs/subj 0.2689 0.2781 5.58E-01 0.0773 0.0810 6.42E-01       
Subjs w CNV 0.2244 0.2274 4.20E-01 0.0706 0.0723 5.06E-01       
Genes/CNV 2.7030 2.6270 2.47E-01 0.6865 0.6951 5.56E-01       
Genes/CNV kb 0.0999 0.0966 4.29E-01 0.0908 0.0951 8.16E-01       
Intronic CNVs/subj 0.0607 0.0631 4.38E-01 0.0152 0.0204 9.61E-01       
Subjs w CNV 0.0581 0.0590 3.08E-01 0.0151 0.0201 9.61E-01       
Shown are results of whole genome burden analyses on combined data of only CNV calls reported by both QuantiSNP and PennCNV from 
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Table S19. Global burden analyses of CNVs after excluding nominally significant CNV regions that failed manual checks. 
 
CNV type  
CNVs/subject 
OR 95% CI p value 
Cases Cont 
Deletions 
>100kb — All 0.324 0.318 1.0296 0.9658-1.0975 3.71E-01 
    Intergenic 0.134 0.138 0.9881 0.8956-1.0899 8.11E-01 
    Genic 0.191 0.181 1.0606 0.9754-1.1531 1.68E-01 
      Exonic 0.175 0.168 1.0521 0.9646-1.1475 2.51E-01 
      Intronic 0.015 0.012 1.1672 0.8591-1.5876 3.23E-01 
<100kb — All 1.014 0.977 1.0481 1.0137-1.0841 6.13E-03 
    Intergenic 0.506 0.483 1.0711 1.0185-1.1265 7.51E-03 
    Genic 0.508 0.494 1.0343 0.9877-1.0842 1.56E-01 
      Exonic 0.329 0.310 1.0539 0.9953-1.1178 7.61E-02 
      Intronic 0.178 0.184 0.9978 0.9172-1.0855 9.60E-01 
Duplications 
>100kb — All 0.496 0.476 1.0262 0.9830-1.0718 2.40E-01 
    Intergenic 0.087 0.079 1.0912 0.9654-1.2333 1.62E-01 
    Genic 0.409 0.397 1.0179 0.9716-1.0669 4.56E-01 
      Exonic 0.405 0.395 1.0159 0.9695-1.0649 5.10E-01 
      Intronic 0.004 0.002 1.5254 0.7880-3.0095 2.13E-01 
<100kb — All 0.668 0.701 0.9831 0.9493-1.0175 3.33E-01 
    Intergenic 0.250 0.265 0.9736 0.9116-1.0395 4.23E-01 
    Genic 0.417 0.436 0.9838 0.9402-1.0288 4.76E-01 
      Exonic 0.344 0.364 0.9729 0.9251-1.0224 2.80E-01 
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Table S20. DNA sample sources of the subjects included in this dataset. 
 
Cohort # Cases # Controls Total Source 
RADIANT 2,460 2,587 5,047 Blood 
NESDA/NTR 1,568 1,913 3,481 Blood 
GenRED II 811 862 1,673 Blood (137 cases & 862 controls); LCL (674 cases) 




Table S21. CNV burden comparison between blood vs. LCL case DNAs in cohort GenRED II. 
 




Blood LCL OR 2.50% 97.50% p value 
Long deletion (>100kb) 
All 0.2920 0.3991 0.9815 0.7078 0.4923 0.9908 5.21E-02 
Genic 0.1679 0.2211 0.9243 0.7343 0.4513 1.1443 1.91E-01 
Exonic 0.1606 0.1929 0.8290 0.8158 0.4948 1.2868 4.01E-01 
Intronic 0.0073 0.0282 0.9768 0.2527 0.0140 1.2340 1.82E-01 
Intergenic 0.1241 0.1780 0.9401 0.6943 0.4011 1.1241 1.63E-01 
Short deletion (<100kb) 
All 1.6060 1.7200 0.8107 0.9439 0.8237 1.0747 3.94E-01 
Genic 0.7883 0.8442 0.7501 0.9373 0.7633 1.1394 5.25E-01 
Exonic 0.4818 0.5549 0.8678 0.8710 0.6657 1.1193 2.96E-01 
Intronic 0.3066 0.2893 0.3909 1.0616 0.7467 1.4735 7.29E-01 
Intergenic 0.8175 0.8754 0.7488 0.9407 0.7720 1.1331 5.31E-01 
Long duplication (>100kb) 
All 0.5839 0.5623 0.4026 1.0348 0.8164 1.2943 7.71E-01 
Genic 0.4745 0.4451 0.3477 1.0594 0.8138 1.3579 6.58E-01 
Exonic 0.4599 0.4407 0.4075 1.0389 0.7956 1.3345 7.72E-01 
Intronic 0.0146 0.0045 0.1994 3.3495 0.4369 20.4738 1.89E-01 
Intergenic 0.1095 0.1172 0.6413 0.9321 0.5123 1.5852 8.06E-01 
Short duplication (<100kb) 
All 1.1610 1.0820 0.2409 1.0589 0.9042 1.2298 4.64E-01 
Genic 0.8029 0.6988 0.1121 1.1387 0.9277 1.3859 2.03E-01 
Exonic 0.6861 0.5816 0.0919 1.1696 0.9348 1.4501 1.60E-01 
Intronic 0.1168 0.1172 0.5465 0.9964 0.5647 1.6434 9.89E-01 
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Table S22. Logistic regression analyses of global burden of CNVs for RADIANT cases vs. screened controls and for RADIANT 
cases vs. unscreened NBS samples. 
 
Type of Deletion Type of CNV 
RADIANT cases vs 
screened controls 
RADIANT cases vs  
unscreened NBS controls 
OR 2.50% 97.50% p value OR 2.50% 97.50% p value 
Long (>100kb) 
All 1.0562 0.8677 1.2989 5.95E-01 1.0237 0.9185 1.1412 6.72E-01 
Gene-containing 1.1273 0.8654 1.4975 3.91E-01 0.9480 0.8241 1.0903 4.54E-01 
Exon-containing 1.1201 0.8527 1.5036 4.32E-01 0.9115 0.7892 1.0522 2.06E-01 
Intronic 1.1757 0.5023 3.4380 7.36E-01 1.6856 0.9747 2.9992 6.70E-02 
Intergenic 0.9742 0.7336 1.3201 8.61E-01 1.1473 0.9673 1.3625 1.16E-01 
Short (<100kb) 
All 1.2721 1.0750 1.5182 6.23E-03 1.0155 0.9321 1.1064 7.26E-01 
Gene-containing 1.2706 1.0205 1.6042 3.77E-02 1.1333 1.0085 1.2745 3.61E-02 
Exon-containing 1.4719 1.1164 1.9870 8.44E-03 1.2161 1.0566 1.4018 6.64E-03 
Intronic 0.9559 0.6774 1.3953 8.06E-01 0.9684 0.7883 1.1903 7.60E-01 
Intergenic 1.2856 0.9898 1.7026 6.89E-02 0.8885 0.7810 1.0107 7.21E-02 
 
 
Type of Duplication Type of CNV 
RADIANT cases vs 
screened controls 
RADIANT cases vs  
unscreened NBS controls 
OR 2.50% 97.50% p value OR 2.50% 97.50% p value 
Long (>100kb) 
All 0.9264 0.8153 1.0606 2.53E-01 0.9382 0.8696 1.0119 9.85E-02 
Gene-containing 0.9502 0.8180 1.1151 5.17E-01 0.8884 0.8156 0.9671 6.43E-03 
Exon-containing 0.9431 0.8118 1.1070 4.58E-01 0.8876 0.8146 0.9666 6.29E-03 
Intronic Inf NA NA NA 0.9660 0.3394 2.8165 9.48E-01 
Intergenic 0.8162 0.6137 1.1100 1.77E-01 1.2185 1.0047 1.4819 4.59E-02 
Short (<100kb) 
All 1.0419 0.8939 1.2257 6.10E-01 0.9938 0.9157 1.0784 8.81E-01 
Gene-containing 1.0559 0.8753 1.2920 5.83E-01 0.9648 0.8756 1.0625 4.67E-01 
Exon-containing 1.0521 0.8571 1.3119 6.40E-01 0.9325 0.8392 1.0350 1.91E-01 
Intronic 1.0921 0.6661 1.9180 7.42E-01 1.2533 0.9319 1.6942 1.38E-01 
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Table S23. CNV burden in regulatory regions. 
 
Tissues 
Enhancer regions Non-enhancer regions 
AFF UNAFF LR p-value AFF UNAFF LR p-value 
K562 Leukemia Cells 0.0701 0.0607 0.0146 0.4362 0.4224 0.0502 
All tissues combined 0.4254 0.4093 0.0240 0.0808 0.0738 0.1015 
Foreskin Keratinocyte Primary Cells skin03 0.1519 0.1401 0.0262 0.3543 0.3430 0.0751 
Primary B cells from peripheral blood 0.0514 0.0444 0.0398 0.4548 0.4387 0.0295 
hESC Derived CD56+ Mesoderm Cultured Cells 0.1166 0.1065 0.0477 0.3896 0.3765 0.0455 
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Table S24. Regional tests on known regions associated with psychiatric disorders. 
 
Regions (hg19) Chr Start End # Deletions in cases 




# Duplications in 
cases 




1q21.1 1 145,934,643 147,709,376 2 2 0.638 2 5 1.000 
NRXN1 2 50,147,488 51,259,674 25 17 0.077 2 2 0.637 
3q29 3 195,745,603 197,355,603 2 3 1.000 7 12 1.000 
7q11.21 7 64,838,768 64,865,998 0 0 1.000 0 0 1.000 
7q11.23 7 72,742,064 74,142,064 1 1 0.669 1 2 1.000 
7p36.3 7 158,453,198 158,972,237 1 0 0.562 4 5 1.000 
8q22.2 8 100,025,494 100,889,808 0 2 1.000 2 0 0.147 
9p24.3 9 841,690 969,090 1 2 1.000 2 0 0.107 
13q12.11 13 20,411,593 20,437,773 0 0 1.000 0 1 1.000 
15q11.2 15 22,798,636 23,088,559 13 15 1.000 15 9 0.090 
AS/PWS 15 24,820,000 28,430,000 9 6 0.149 3 1 0.243 
15q13.3 15 31,132,708 32,482,708 3 6 1.000 38 34 0.270 
16p13.11 16 15,510,000 16,300,000 11 19 1.000 14 18 1.000 
16p11.2 distal 16 28,822,499 29,052,499 0 2 1.000 1 3 1.000 
16p11.2 proximal 16 29,652,499 30,202,499 3 4 1.000 6 3 0.305 
17p12 17 14,160,000 15,430,000 4 1 0.255 1 1 0.772 
17q12 17 34,810,000 36,200,000 1 0 0.475 1 1 0.600 
22q11.2 22 19,020,000 21,420,000 15 16 0.487 17 17 0.517 
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Table S25. Regional tests on known regions associated with developmental delay. 
 
Regions (hg19) # Deletions in cases # Deletions in controls EMP1 of deletions # Duplications in cases # Duplications in controls EMP1 of duplication 
chr1:710,137-9,977,413 34 38 0.566 62 93 1.000 
chr1:860,137-3,660,140 9 19 1.000 42 67 1.000 
chr1:145,338,643-147,883,376 7 8 0.641 28 25 0.326 
chr1:171,733,377-172,333,377 0 0 1.000 0 0 1.000 
chr1:242,433,377-246,733,377 9 8 0.415 9 14 1.000 
chr1:245,033,377-248,833,377 17 24 1.000 19 29 1.000 
chr2:110,000-1,720,993 7 11 1.000 5 19 1.000 
chr2:3,270,993-3,470,993 0 0 1.000 0 0 1.000 
chr2:45,346,496-46,046,496 2 2 0.694 6 2 0.148 
chr2:111,333,937-113,133,529 1 5 1.000 3 4 1.000 
chr2:111,333,937-113,233,529 1 5 1.000 3 4 1.000 
chr2:165,691,754-166,391,754 0 2 1.000 0 1 1.000 
chr2:235,735,261-243,102,476 11 4 0.032 49 40 0.120 
chr3:125,000-925,000 8 8 0.389 7 8 0.569 
chr3:825,000-1,425,000 6 3 0.165 10 7 0.405 
chr3:2,125,000-9,825,000 129 106 0.005 17 14 0.368 
chr3:195,715,603-197,415,603 2 3 1.000 7 12 1.000 
chr4:110,000-7,049,099 50 35 0.031 42 51 1.000 
chr4:360,000-3,913,620 10 9 0.327 37 45 1.000 
chr4:9,840,902-10,841,902 5 7 1.000 0 7 1.000 
chr4:81,730,976-83,130,976 0 0 1.000 0 4 1.000 
chr4:184,013,006-184,513,006 0 0 1.000 0 1 1.000 
chr4:187,263,006-187,963,006 0 3 1.000 2 1 0.452 
chr5:47,000-1,447,000 6 8 1.000 44 40 0.192 
chr5:3,697,000-4,397,000 0 0 1.000 3 1 0.216 
chr5:175,517,394-177,517,394 25 18 0.093 3 5 1.000 
chr5:180,117,394-180,817,394 1 1 0.818 27 26 0.389 
chr6:155,000-5,855,001 24 34 1.000 18 33 1.000 
chr6:20,742,021-21,142,021 2 0 0.150 1 0 0.584 
chr6:165,330,010-170,908,075 9 6 0.213 11 23 1.000 
chr7:10,239-3,833,474 27 36 1.000 23 27 1.000 
chr7:5,733,474-6,233,475 2 1 0.276 6 2 0.179 
chr7:72,662,064-74,262,064 1 1 0.670 1 2 1.000 
chr8:160,000-11,912,591 180 191 0.196 84 104 1.000 
chr8:360,000-1,062,593 3 5 1.000 5 3 0.207 
chr8:2,362,593-4,362,592 39 30 0.050 5 6 1.000 
chr8:8,212,590-11,912,591 17 36 1.000 10 12 1.000 
chr8:53,287,447-53,887,447 0 0 1.000 6 19 1.000 
chr8:143,252,093-145,979,195 26 15 0.055 34 60 1.000 
chr9:160,000-1,660,000 32 41 1.000 46 54 1.000 
chr9:160,000-6,760,000 74 83 0.452 66 77 1.000 
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Regions (hg19) # Deletions in cases # Deletions in controls EMP1 of deletions # Duplications in cases # Duplications in controls EMP1 of duplication 
chr10:2,610,000-3,210,000 0 3 1.000 2 5 1.000 
chr10:81,610,020-88,910,020 16 21 1.000 31 24 0.072 
chr10:127,760,010-135,400,010 7 11 1.000 20 28 1.000 
chr11:310,000-3,443,424 7 7 0.509 9 14 1.000 
chr11:128,044,790-134,844,790 14 21 1.000 72 77 0.313 
chr12:229,739-3,629,739 15 13 0.330 20 24 1.000 
chr12:279,739-779,739 5 4 0.441 3 2 0.585 
chr12:8,158,733-8,358,733 0 1 1.000 0 0 1.000 
chr13:19,402,000-20,302,000 0 1 1.000 6 6 0.504 
chr14:36,430,249-37,230,249 0 0 1.000 3 0 0.122 
chr14:104,480,247-106,378,955 15 3 0.004 44 20 0.002 
chr15:22,648,636-28,626,405 49 50 0.145 46 38 0.082 
chr15:22,648,636-31,912,708 59 63 0.200 61 53 0.112 
chr15:30,862,708-32,962,708 10 10 0.489 38 35 0.316 
chr15:85,098,996-85,798,996 9 3 0.063 4 2 0.294 
chr15:100,382,477-102,382,477 12 16 1.000 55 54 0.355 
chr15:101,032,477-101,732,477 5 1 0.093 3 1 0.299 
chr16:160,000-5,209,999 15 24 1.000 41 34 0.093 
chr16:709,999-2,509,999 6 0 0.009 13 10 0.208 
chr16:3,709,999-5,209,999 7 20 1.000 1 2 1.000 
chr16:14,892,499-16,912,499 24 32 1.000 35 42 1.000 
chr16:14,892,499-18,292,499 24 32 1.000 37 44 1.000 
chr16:21,892,499-22,492,499 5 4 0.458 2 6 1.000 
chr16:28,442,499-30,342,499 5 6 1.000 9 8 0.511 
chr16:83,792,499-90,222,499 35 30 0.218 18 24 1.000 
chr16:87,742,499-90,172,499 8 11 1.000 14 11 0.240 
chr17:100,000-4,153,251 16 27 1.000 21 29 1.000 
chr17:703,250-1,603,250 4 3 0.527 17 14 0.275 
chr17:16,659,275-25,475,873 40 24 0.008 23 40 1.000 
chr17:16,709,275-20,309,408 24 11 0.010 6 8 1.000 
chr17:29,025,874-29,825,880 0 4 1.000 4 0 0.087 
chr17:34,725,887-36,295,000 1 0 0.473 2 2 0.581 
chr17:34,775,887-36,275,614 1 0 0.473 2 2 0.581 
chr17:43,644,217-44,144,178 0 0 1.000 3 2 0.497 
chr17:72,088,405-81,060,000 7 10 1.000 46 53 1.000 
chr18:110,000-5,310,000 61 57 0.137 10 17 1.000 
chr18:6,760,000-7,360,000 0 1 1.000 2 2 0.638 
chr18:70,949,020-77,899,009 9 16 1.000 27 15 0.025 
chr19:199,000-5,899,000 5 9 1.000 41 34 0.060 
chr19:199,000-8,789,000 19 27 1.000 75 82 0.344 
chr19:54,858,188-59,058,188 10 18 1.000 20 38 1.000 
chr20:152,000-1,162,000 2 1 0.507 6 7 1.000 
chr21:21,028,129-21,328,129 20 14 0.060 1 0 0.563 
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Regions (hg19) # Deletions in cases # Deletions in controls EMP1 of deletions # Duplications in cases # Duplications in controls EMP1 of duplication 
chr22:17,470,000-25,020,000 48 43 0.157 39 39 0.505 
chr22:18,820,000-22,270,000 41 41 0.318 27 26 0.385 
chr22:23,370,000-23,770,000 0 0 1.000 0 0 1.000 
chr22:25,370,000-26,170,000 1 0 0.476 2 2 0.557 
chr22:44,268,667-51,244,566 19 39 1.000 25 27 0.267 


















Figure S1. Statistical power to detect single CNV loci associated with MDD. Different colors represent 
different power intervals over the genotypic relative risk (y axis) and the risk allele frequency in the population 
(x axis). Calculations were based on 5780 cases, 6626 controls, a dominant model, lifetime risk of MDD of 10% 




































Figure S3. Odds ratios and 95% confidence intervals of short deletions of various sizes. The size of the 































ACCEPTED MANUSCRIPTZhang et al.  Supplement 
 47 
Figure S5. Plots of 15q11.2 dups, 6q21 dups, 8p22 dels, and 6q26 dels 
 
Shown below are plots of CNVs in the four independent regions listed in Table 3, for both case and control 
carriers. All CNVs in the dataset are shown for 15q11.2 duplications, 6q21 duplications. For the more frequent 
CNVs, 15 CNVs were randomly selected from among the 92 8p22 deletions and 15 from among the 105 6q26 
deletions. Plots of all CNVs in these regions, and for randomly selected negative controls, are available on request.  
 
In each plot, the copy number and the position of the CNV boundaries are shown in the top, as called by Birdsuite 
for Affymetrix data or QuantiSNP for Illumina data. The physical positions of CNVs in the GenRED-II cohort are 
based on hg19 while the positions for all the other cohorts are based on hg18 (although for statistical analyses in 
this paper, all hg18 coordinates were lifted over to hg19). 
 
X-axis values are bp locations. Y-axis values are Log R Ratio [LRR] (upper panels) and B Allele Frequency 
[BAF] (lower panels). Blue vertical lines represent the CNV boundaries reported by Birdsuite for Affymetrix data 
or QuantiSNP for Illumina data. The red dots are the point-by-point copy number estimates made by an alternative 
algorithm (Lai et al., 2008).  
 
Lai TL, Xing H, Zhang N (2008): Stochastic segmentation models for array-based comparative genomic hybridization data 
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NESDA/NTR Case duplication (hg18) 
























































RADIANT Control duplication (hg18) 
GenRED Case duplication (hg18) 
GenRED Control duplication (hg18) 











































   
NESDA/NTR Case duplication (hg18) 
































    
 
 
GenRED Case duplication (hg18) 
NESDA/NTR Case deletion (hg18) 
NESDA/NTR Control deletion (hg18) 



































RADIANT Control deletion (hg18) 
GenRED Case deletion (hg18) 
GenRED Control deletion (hg18) 


































   
GenRED-II Control deletion (hg19) 
NESDA/NTR Case deletion (hg18) 
NESDA/NTR Control deletion (hg18) 



































RADIANT Control deletion (hg18) 
GenRED Case deletion (hg18) 
GenRED Control deletion (hg18) 
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Codes for the analysis pipeline: PLINK command and R scripts used in the analyses 
 
######################################################################## 
Permutation test for global burden of rare CNV 
######################################################################## 
 
# Exonic deletions  
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 100 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_Exons.txt \ 
--out Del_100kb_exon_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_Exons.txt \ 
--out Del_100kb_singleton_exon_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 500 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_Exons.txt \ 
--out Del_500kb_exon_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 1000 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_Exons.txt \ 
--out Del_1000kb_exon_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-indiv-perm \ 
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--cnv-count hg19_Exons.txt \ 
--out Del_small_exon_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_Exons.txt \ 
--out Del_small_singleton_exon_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 100 \ 
--cnv-intersect hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_100_exon_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-intersect hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_100_singleton_exon_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 500 \ 
--cnv-intersect hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_500_exon_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 1000 \ 
--cnv-intersect hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_1000_exon_intersect 
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--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-intersect hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_small_exon_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-intersect hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_small_singleton_exon_intersect 
 
# Genic deletions 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 100 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_RefGenes.txt \ 
--out Del_100kb_gene_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_RefGenes.txt \ 
--out Del_100kb_singleton_gene_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 500 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_RefGenes.txt \ 
--out Del_500kb_gene_count 
 
plink --noweb \ 
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--cnv-kb 1000 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_RefGenes.txt \ 
--out Del_1000kb_gene_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_RefGenes.txt \ 
--out Del_small_gene_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_RefGenes.txt \ 
--out Del_small_singleton_gene_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 100 \ 
--cnv-intersect hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_100_gene_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-intersect hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_100_singleton_gene_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 500 \ 
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--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_500_gene_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 1000 \ 
--cnv-intersect hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_1000_gene_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-intersect hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_small_gene_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-intersect hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_small_singleton_gene_intersect 
 
# Exonic duplications 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 100 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_Exons.txt \ 
--out Dup_100kb_exon_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
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plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 500 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_Exons.txt \ 
--out Dup_500kb_exon_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 1000 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_Exons.txt \ 
--out Dup_1000kb_exon_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_Exons.txt \ 
--out Dup_small_exon_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_Exons.txt \ 
--out Dup_small_singleton_exon_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 100 \ 
--cnv-intersect hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_100_exon_intersect 
 
plink --noweb \ 
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--cnv-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-intersect hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_100_singleton_exon_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 500 \ 
--cnv-intersect hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_500_exon_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 1000 \ 
--cnv-intersect hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_1000_exon_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-intersect hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_small_exon_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-intersect hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_small_singleton_exon_intersect 
 
# Genic duplications 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
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--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_RefGenes.txt \ 
--out Dup_100kb_gene_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_RefGenes.txt \ 
--out Dup_100kb_singleton_gene_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 500 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_RefGenes.txt \ 
--out Dup_500kb_gene_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 1000 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_RefGenes.txt \ 
--out Dup_1000kb_gene_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--cnv-count hg19_RefGenes.txt \ 
--out Dup_small_gene_count 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
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plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 100 \ 
--cnv-intersect hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_100_gene_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-intersect hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_100_singleton_gene_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 500 \ 
--cnv-intersect hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_500_gene_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 1000 \ 
--cnv-intersect hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_1000_gene_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-intersect hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_small_gene_intersect 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
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--cnv-max-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-intersect hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_small_singleton_gene_intersect 
 
# Intergenic duplications 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 100 \ 
--cnv-exclude hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_100_intergenic 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-exclude hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_100_singleton_intergenic 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 500 \ 
--cnv-exclude hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_500_intergenic 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 1000 \ 
--cnv-exclude hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_1000_intergenic 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
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--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_small_intergenic 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-exclude hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_small_singleton_intergenic 
 
# Intergenic deletions  
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 100 \ 
--cnv-exclude hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_100_intergenic 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-exclude hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_100_singleton_intergenic 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 500 \ 
--cnv-exclude hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_500_intergenic 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 1000 \ 
--cnv-exclude hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
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plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-exclude hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_small_intergenic 
 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-exclude hg19_RefGenes.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_small_singleton_intergenic 
 
######## Intronic deletions 
#### For large deletions 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 100 \ 




## Make map file 
plink --noweb \ 
--cnv-list Del_100_genic.cnv --cnv-make-map --out Del_100_genic 
 
plink --noweb \ 
--cfile Del_100_genic \ 
--cnv-exclude hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_100_intronic 
 
plink --noweb \ 
--cfile Del_100_genic \ 
--cnv-del \ 
--cnv-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-exclude hg19_Exons.txt \ 
--cnv-indiv-perm \ 
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plink --noweb \ 
--cfile Del_100_genic \ 
--cnv-del \ 
--cnv-kb 500 \ 
--cnv-exclude hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_500_intronic 
 
plink --noweb \ 
--cfile Del_100_genic \ 
--cnv-del \ 
--cnv-kb 1000 \ 
--cnv-exclude hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_1000_intronic 
 
#### For small deletions 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-del \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 




## Make map file 
plink --noweb \ 
--cnv-list Del_small_genic.cnv --cnv-make-map --out Del_small_genic 
 
plink --noweb \ 
--cfile Del_small_genic \ 
--cnv-exclude hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_small_intronic 
 
plink --noweb \ 
--cfile Del_small_genic \ 
--cnv-del \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-exclude hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Del_small_singleton_intronic 
 
######## Intronic duplications 
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plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
--cnv-kb 100 \ 




## Make map file 
plink --noweb \ 
--cnv-list Dup_100_genic.cnv --cnv-make-map --out Dup_100_genic 
 
plink --noweb \ 
--cfile Dup_100_genic \ 
--cnv-exclude hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_100_intronic 
 
plink --noweb \ 
--cfile Dup_100_genic \ 
--cnv-dup \ 
--cnv-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-exclude hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_100_singleton_intronic 
 
plink --noweb \ 
--cfile Dup_100_genic \ 
--cnv-dup \ 
--cnv-kb 500 \ 
--cnv-exclude hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_500_intronic 
 
plink --noweb \ 
--cfile Dup_100_genic \ 
--cnv-dup \ 
--cnv-kb 1000 \ 
--cnv-exclude hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_1000_intronic 
 
#### For small duplications 
plink --noweb \ 
--cfile Filter_Rare_CNV \ 
--cnv-dup \ 
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--cnv-max-kb 100 \ 




## Make map file 
plink --noweb \ 
--cnv-list Dup_small_genic.cnv --cnv-make-map --out Dup_small_genic 
 
plink --noweb \ 
--cfile Dup_small_genic \ 
--cnv-exclude hg19_Exons.txt \ 
--cnv-indiv-perm \ 
--mperm 100000 --within Sex_Batch_cluster.txt \ 
--out Dup_small_intronic 
 
plink --noweb \ 
--cfile Dup_small_genic \ 
--cnv-dup \ 
--cnv-kb 9 \ 
--cnv-max-kb 100 \ 
--cnv-freq-exclude-above 1 \ 
--cnv-exclude hg19_Exons.txt \ 
--cnv-indiv-perm \ 





R scripts for logistic regression of global burden of rare CNV 
######################################################################## 
files<-list.files("input_folder") 
for(i in 1:length(files)){ 
  readpath<-paste("input_folder",files[i], sep="/") 
  data<-read.table(readpath,header=TRUE) 
  mylogit<-glm(Phenotype ~ NSEG+Sex+Batch, data=data, family = "binomial") 
  writepath<-paste("output_folder/GLM_NSEG_OR",files[i], sep="") 
  write.table(exp(cbind(OR = coef(mylogit), confint(mylogit))),writepath) 
  writepath<-paste("output_folder/GLM_NSEG_p_value",files[i], sep="") 
  write.table(summary(mylogit)[["coefficients"]],writepath)  






























Permutation test of exonic CNVs on individual gene 
######################################################################## 
#### Test one gene at a time as some genes overlap. 
plink --noweb \ 
--cfile All_filtered_CNVs \ 




plink --noweb \ 




plink --noweb \ 
--cfile Gene_Exonic_CNV \ 
--cnv-del \ 
--cnv-intersect Gene_region.txt \ 
--cnv-test-region \ 
--mperm 100000 \ 
--within Sex_Batch_cluster.txt \ 
--out All_del 
 
plink --noweb \ 
--cfile Gene_Exonic_CNV \ 
--cnv-dup \ 
--cnv-intersect Gene_region.txt \ 
--cnv-test-region \ 
--mperm 100000 \ 















for(i in 1:length(cnv_count$V1)){ 
  try<-c(cnv_count$V9[i],cnv_count$V8[i],724-cnv_count$V9[i],1240-cnv_count$V8[i], 
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cnv_count$V13[i],cnv_count$V12[i],139-cnv_count$V13[i],384-cnv_count$V12[i], 
cnv_count$V15[i],cnv_count$V14[i],672-cnv_count$V15[i],478-cnv_count$V14[i],    
cnv_count$V17[i],cnv_count$V16[i],271-cnv_count$V17[i],743-cnv_count$V16[i],  
cnv_count$V19[i],cnv_count$V18[i],670-cnv_count$V19[i],521-cnv_count$V18[i],    
cnv_count$V21[i],cnv_count$V20[i],488-cnv_count$V21[i],719-cnv_count$V20[i], 
cnv_count$V23[i],cnv_count$V22[i],1080-cnv_count$V23[i],1194-cnv_count$V22[i]) 
  dim(try)<-c(2,2,8) 












  rm(try) 






Permutation test on segment groups 
######################################################################## 
plink --noweb \ 




plink --noweb \ 




plink --noweb \ 
--cfile Del_all \ 
--cnv-intersect Deletion_segment-group_region.txt \ 
--cnv-test-region \ 
--mperm 100000 \ 
--within Sex_Batch_cluster.txt \ 
--out Del_segment_test 
 
plink --noweb \ 
--cfile Dup_all \ 
--cnv-intersect Duplication_segment-group_region.txt \ 
--cnv-test-region \ 
--mperm 100000 \ 




























for(i in 1:length(cnv_count$V1)){ 
  try<-c(cnv_count$V9[i],cnv_count$V8[i],724-cnv_count$V9[i],1240-cnv_count$V8[i], 
cnv_count$V11[i],cnv_count$V10[i],1736-cnv_count$V11[i],1347-cnv_count$V10[i],   
cnv_count$V13[i],cnv_count$V12[i],139-cnv_count$V13[i],384-cnv_count$V12[i], 
cnv_count$V15[i],cnv_count$V14[i],672-cnv_count$V15[i],478-cnv_count$V14[i],    
cnv_count$V17[i],cnv_count$V16[i],271-cnv_count$V17[i],743-cnv_count$V16[i],  
cnv_count$V19[i],cnv_count$V18[i],670-cnv_count$V19[i],521-cnv_count$V18[i],    
cnv_count$V21[i],cnv_count$V20[i],488-cnv_count$V21[i],719-cnv_count$V20[i], 
cnv_count$V23[i],cnv_count$V22[i],1080-cnv_count$V23[i],1194-cnv_count$V22[i]) 
  dim(try)<-c(2,2,8) 












  rm(try) 
  rm(CHM_output) 
} 
